Il-4 / il-13 pathway inhibitors for enhanced efficacy in treating cancer
Combining an IL-4/IL-13 pathway inhibitor with a PD-1 inhibitor targets type 2 immune mechanisms in cancers, overcoming resistance to PD-1 blockade and improving treatment outcomes in pancreatic cancer.
Patent Information
- Application Number
- JP2024146134
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2020-01-28
- Filing Date
- 2024-08-28
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2040-02-28
AI Technical Summary
There is a need for effective therapies to treat cancers, including those with a type 2 immune response and those resistant to prior treatments, particularly pancreatic cancer which is resistant to immune checkpoint blockade due to its desmoplastic stroma and immunosuppressive environment.
Administering a therapeutically effective amount of an IL-4/IL-13 pathway inhibitor in combination with a PD-1 inhibitor to target type 2 immune-dependent mechanisms in cancers, enhancing the antitumor efficacy of PD-1 blockade.
The combination therapy promotes tumor regression, reduces tumor growth, and increases survival in subjects with type 2 immune-dependent cancers, including pancreatic cancer, by enhancing the response to PD-1 blockade.
Smart Images

Figure 2024167311000002 
Figure 2024167311000003 
Figure 2024167311000004
Abstract
Description
[Technical field]
[0001] FIELD OF THEINVENTION The present disclosure relates to methods for treating cancer comprising administering to a subject in need thereof a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor in combination with a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor, hi certain embodiments, the IL-4 / IL-13 pathway inhibitor enhances the anti-tumor efficacy of PD-1 blockade. [Background technology]
[0002] background Type 2 immunity promotes tumor growth and metastasis in various cancer types. Several type 2-related cytokines, chemokines or receptors are involved in cancer and are overexpressed in various human tumors. For example, IL-4, IL-13, IL-4Rα, and IL-33 are overexpressed in many human cancer types and are associated with poor prognosis in bladder, breast or ovarian cancer (Non-Patent Document 1; Non-Patent Document 2; Non-Patent Document 3). Type 2 immunity is characterized by the production of many type 2 cytokines and chemokines (e.g., IL-4, IL-13, thymic stromal lymphopoietin (TSLP), IL-33) and is commonly found in tissues during allergic responses or anti-parasitic infections. Type 2 immune responses also contribute to tissue repair responses and fibrosis (Non-Patent Document 4; Non-Patent Document 5).
[0003] Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the United States, with a 5-year survival rate of 8%. This very poor prognosis is mainly due to PDAC being resistant to most treatments. In particular, immune checkpoint blockade (ICB) immunotherapy (e.g., anti-PD-1 or anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4)) fails to produce clinical responses in PDAC patients. The main contributor to the strong drug resistance in PDAC is its unique desmoplastic stroma - a dense fibrotic and stromal reaction composed of cancer-associated fibroblasts, immune cells and a large amount of extracellular matrix components - which acts as a physical barrier to drug perfusion and T-cell infiltration, and creates a severe immunosuppressive environment that inhibits T-cell function (Non-Patent Document 6; Non-Patent Document 7; Non-Patent Document 8).
[0004] Preclinical studies have shown that gene disruption or blocking of IL-13, IL-4R, or TSLP can reduce tumor growth and metastatic burden in pancreatic, breast, and colorectal cancer. Furthermore, serum IL-4 and TSLP have been shown to predict survival in pancreatic cancer patients (Non-Patent Document 9; Non-Patent Document 10). Mechanisms of type 2 immune-dependent tumorigenesis include induction of fibrosis formation, inhibition of antitumor surveillance, or increased glucose and glutamine cancer cell metabolism (Non-Patent Document 11; Non-Patent Document 12; Non-Patent Document 13; Non-Patent Document 14; Non-Patent Document 15). Taken together, these data demonstrate that type 2 immunity promotes tumor growth and metastasis in various cancer types. [Prior art documents] [Non-patent literature]
[0005] [Non-Patent Document 1] Joshi et al., Cancer Med., 3(6):1615-28, 2014 [Non-Patent Document 2] Formentini et al., Int J Colorectal Dis., 27(10):1369-76, 2012 [Non-Patent Document 3] Tong et al., Mol Oncol. 10(1):113-25, 2015
Non-licensed Document 4
Non-licensed Document 5
Non-licensed Document 6
Non-licensed Document 7
Non-licensed literature 9
Non-licensed literature 10
Non-licensed Document 11
Non-licensed Document 12
Non-licensed Document 13
Non-licensed Document 14
Non-licensed Document 15
[0006] Thus, there is a need for new effective therapies to treat cancer, including cancers and subsets of cancer types characterized by a type 2 immune response, as well as cancers that are resistant to prior therapies. [Means for solving the problem]
[0007] Abstract In one aspect, the disclosed technology relates to a method of treating or inhibiting the growth of a tumor, the method comprising: (a) selecting a subject having a tumor; and (b) administering to a subject in need thereof a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor. In one embodiment, the subject has a tumor selected from the group consisting of colorectal cancer, ovarian cancer, prostate cancer, bladder cancer, breast cancer, brain cancer, cervical cancer, bladder cancer, anal cancer, uterine cancer, colon cancer, liver cancer, pancreatic cancer, lung cancer, endometrial cancer, bone cancer, testicular cancer, skin cancer, renal cancer, gastric cancer, esophageal cancer, head and neck cancer, salivary gland cancer, myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, B-cell lymphoma, lymphomatoid granulomatosis, Burkitt's lymphoma, acute lymphocytic leukemia, hairy cell leukemia, and B-cell chronic lymphocytic leukemia. In one embodiment, the tumor comprises a type 2 immune-dependent cancer. In another embodiment, the type 2 immune-dependent cancer includes pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, brain cancer, skin cancer, prostate cancer, kidney cancer, lung cancer, Hodgkin's lymphoma, or bladder cancer. In another embodiment, the tumor comprises pancreatic cancer. In one embodiment, the tumor is primary, metastatic, or recurrent. In one embodiment, the subject has been treated with one or more anti-cancer therapies. In one embodiment, the subject is refractory or unsuitable for prior treatment. In one embodiment, the subject has a tumor that is resistant or non-responsive to treatment with an immune checkpoint inhibitor (e.g., a PD-1 inhibitor, a LAG3 inhibitor, etc.).
[0008] In one embodiment, the IL-4 / IL-13 pathway inhibitor is selected from the group consisting of an anti-IL-4 antibody, an anti-IL-13 antibody, an anti-IL-4 / IL-13 bispecific antibody, an IL-4 receptor (IL-4R) inhibitor, an IL-4 trap, an IL-13 trap, and an anti-IL-4R antibody. In another embodiment, the IL-4 / IL-13 pathway inhibitor is an anti-IL-4 antibody (e.g., pascolizumab). In another embodiment, the IL-4 / IL-13 pathway inhibitor is an anti-IL-13 antibody (e.g., tralokinumab, lebrikizumab, dectrekumab, GSK679586, or MEDI7836). In another embodiment, the IL-4 / IL-13 pathway inhibitor is an anti-IL-4 / IL-13 bispecific antibody (e.g., romilkimab). In another embodiment, the IL-4 / IL-13 pathway inhibitor is an IL-4R inhibitor (e.g., an IL-4 mutein such as pitrakinra or an anti-IL-4R antibody). In another embodiment, the IL-4 / IL-13 pathway inhibitor is an anti-IL-4R antibody. In another embodiment, the IL-4 / IL-13 pathway inhibitor is an IL-4 or IL-13 trap.
[0009] In another embodiment, the anti-IL-4R antibody comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO: 1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO: 2. In another embodiment, the HCVR comprises three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) and the LCVR comprises three light chain CDRs (LCDR1, LCDR2 and LCDR3), where: HCDR1 has the amino acid sequence of SEQ ID NO: 3; HCDR2 has the amino acid sequence of SEQ ID NO: 4; HCDR3 has the amino acid sequence of SEQ ID NO: 5; LCDR1 has the amino acid sequence of SEQ ID NO: 6; LCDR2 has the amino acid sequence of SEQ ID NO: 7; and LCDR3 has the amino acid sequence of SEQ ID NO: 8. In another embodiment, the anti-IL-4R antibody comprises a heavy chain and a light chain, where the heavy chain has the amino acid sequence of SEQ ID NO: 9. In another embodiment, the anti-IL-4R antibody comprises a heavy chain and a light chain, where the light chain has the amino acid sequence of SEQ ID NO: 10. In another embodiment, the anti-IL-4R antibody comprises a heavy chain and a light chain, wherein the heavy chain has the amino acid sequence of SEQ ID NO: 9 and the light chain has the amino acid sequence of SEQ ID NO: 10. In another embodiment, the IL-4 / IL-13 pathway inhibitor is dupilumab or a bioequivalent thereof. In another embodiment, the IL-4 / IL-13 pathway inhibitor is selected from the group consisting of dupilumab, pascolizumab, AMG317, MEDI2045, MEDI9314, tralokinumab, lebrikzimab, anrukinzumab, dextrekumab, GSK679586, MEDI7836, romilukimab, IL-4 trap, IL-13 trap, AER-003, and pitrakinra.
[0010] In one embodiment, the PD-1 inhibitor is selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody. In another embodiment, the PD-1 inhibitor is an anti-PD-1 antibody comprising an HCVR comprising the amino acid sequence of SEQ ID NO: 11 and an LCVR comprising the amino acid sequence of SEQ ID NO: 12. In another embodiment, the HCVR comprises three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) and the LCVR comprises three light chain CDRs (LCDR1, LCDR2 and LCDR3), where: HCDR1 has the amino acid sequence of SEQ ID NO: 13; HCDR2 has the amino acid sequence of SEQ ID NO: 14; HCDR3 has the amino acid sequence of SEQ ID NO: 15; LCDR1 has the amino acid sequence of SEQ ID NO: 16; LCDR2 has the amino acid sequence of SEQ ID NO: 17; and LCDR3 has the amino acid sequence of SEQ ID NO: 18. In another embodiment, the anti-PD-1 antibody comprises an HCVR of SEQ ID NO: 11 / 12 / LCVR sequence pair. In another embodiment, the anti-PD-1 antibody comprises a heavy chain and a light chain, wherein the heavy chain has the amino acid sequence of SEQ ID NO: 19. In another embodiment, the anti-PD-1 antibody comprises a heavy chain and a light chain, wherein the light chain has the amino acid sequence of SEQ ID NO: 20. In another embodiment, the anti-PD-1 antibody comprises a heavy chain and a light chain, wherein the heavy chain has the amino acid sequence of SEQ ID NO: 19 and the light chain has the amino acid sequence of SEQ ID NO: 20. In another embodiment, the PD-1 inhibitor is cemiplimab or a biological equivalent thereof. In another embodiment, the PD-1 inhibitor is an anti-PD-1 antibody selected from the group consisting of cemiplimab, nivolumab, pembrolizumab, pidilizumab, MEDI0608, BI 754091, PF-06801591, sintilimab, AGEN2034, spartalizumab, camrelizumab, JNJ-63723283, and MCLA-134. In another embodiment, the PD-1 inhibitor is an anti-PD-L1 antibody selected from the group consisting of H1H8314N, avelumab, atezolizumab, durvalumab, MDX-1105, LY3300054, FAZ053, STI-1014, CX-072, KN035, and CK-301.
[0011] In another embodiment, one or more doses of an IL-4 / IL-13 pathway inhibitor are administered in combination with one or more doses of an anti-PD-1 antibody. In another embodiment, at least one dose of an IL-4 / IL-13 pathway inhibitor comprises about 0.1 to about 50 mg / kg of the subject's body weight. In another embodiment, at least one dose of an IL-4 / IL-13 pathway inhibitor comprises about 0.05 to about 1000 mg of inhibitor. In another embodiment, at least one dose of a PD-1 inhibitor comprises about 0.1 mg / kg to about 20 mg / kg of the subject's body weight. In another embodiment, at least one dose of a PD-1 inhibitor comprises about 0.05 to about 500 mg of inhibitor. In another embodiment, an IL-4 / IL-13 pathway inhibitor is administered prior to a PD-1 inhibitor. In another embodiment, an IL-4 / IL-13 pathway inhibitor is administered after a PD-1 inhibitor. In another embodiment, an IL-4 / IL-13 pathway inhibitor is administered simultaneously with a PD-1 inhibitor. In another embodiment, the method promotes tumor regression, slows tumor growth, reduces tumor cell mass, reduces tumor burden, and / or prevents tumor recurrence in a patient. In another embodiment, the method promotes at least about 10% more tumor regression in a treated subject compared to an untreated subject or a subject treated with either inhibitor as monotherapy. In another embodiment, the method results in at least a 30% or greater reduction in tumor cells or tumor size compared to an untreated subject or a subject treated with either inhibitor as monotherapy.
[0012] In another embodiment, the method further comprises administering at least one additional therapeutic agent or treatment. In another embodiment, the additional therapeutic agent or treatment comprises chemotherapy, cyclophosphamide, surgery, radiation, a cancer vaccine, a LAG3 inhibitor, a CTLA-4 inhibitor, a GITR agonist, a TIM3 inhibitor, a BTLA inhibitor, a TIGIT inhibitor, a CD47 inhibitor, an IDO inhibitor, a VEGF antagonist, an Ang2 inhibitor, a TGFβ inhibitor, an EGFR inhibitor, a VISTA inhibitor, a CD38 inhibitor, a CD40 agonist, a CSF1R inhibitor, a CCR2 inhibitor, a CXCR4 inhibitor, a CXCR2 inhibitor, a CCR4 inhibitor, a CXCL12 inhibitor, a CD28 activator, an agonist for a costimulatory receptor, an antibody for a tumor-specific antigen, an anti-CD3 / anti-CD20 bispecific antibody, GM-CSF, a cytotoxin, a chemotherapeutic agent, an oncolytic virus, an IL-6R inhibitor, an IL-10 inhibitor, a cytokine or derivative thereof (e.g., IL-12 or IL-2), an ADC, a chimeric antigen receptor T cell, an anti-inflammatory drug, an NSAID, and / or a nutritional supplement.
[0013] In another aspect, the disclosed technology provides: (a) IL-4 / IL-13 pathway inhibitors and drugs and (b) a pharmaceutical composition comprising a programmed death 1 (PD-1) inhibitor and a pharma- ceutically acceptable carrier; and a pharmaceutical delivery system comprising the pharmaceutical composition comprising a programmed death 1 (PD-1) inhibitor and a pharma- ceutically acceptable carrier. In one embodiment, pharmaceutical compositions (a) and (b) are separate from one another. In another embodiment, pharmaceutical composition (a) comprises one or more doses of an IL-4 / IL-13 pathway inhibitor. In another embodiment, at least one dose comprises about 5-1000 mg of an IL-4 / IL-13 pathway inhibitor. In another embodiment, pharmaceutical composition (b) comprises one or more doses of a PD-1 inhibitor. In another embodiment, at least one dose comprises about 5-500 mg of a PD-1 inhibitor. In another embodiment, the IL-4 / IL-13 pathway inhibitor is selected from the group consisting of an anti-IL-4 antibody, an anti-IL-13 antibody, an anti-IL-4 / IL-13 bispecific antibody, an IL-4 receptor (IL-4R) inhibitor, an IL-4 trap, an IL-13 trap, and an anti-IL-4R antibody. In another embodiment, the IL-4 / IL-13 pathway inhibitor is selected from the group consisting of dupilumab, pascolizumab, AMG317, MEDI2045, MEDI9314, tralokinumab, lebricizumab, anrukinzumab, dectrekumab, GSK679586, MEDI7836, romilukimab, IL-4 trap, IL-13 trap, AER-003, and pitrakinra. In another embodiment, the PD-1 inhibitor is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody. In another embodiment, the PD-1 inhibitor is an anti-PD-1 antibody selected from the group consisting of cemiplimab, nivolumab, pembrolizumab, pidilizumab, MEDI0608, BI 754091, PF-06801591, sintilimab, AGEN2034, spartalizumab, camrelizumab, JNJ-63723283, and MCLA-134. In another embodiment, the PD-1 inhibitor is an anti-PD-L1 antibody selected from the group consisting of H1H8314N, avelumab, atezolizumab, durvalumab, MDX-1105, LY3300054, FAZ053, STI-1014, CX-072, KN035, and CK-301.
[0014] In another embodiment, the pharmaceutical delivery system further comprises at least one additional therapeutic agent selected from the group consisting of cyclophosphamide, cancer vaccine, LAG3 inhibitor, CTLA-4 inhibitor, GITR agonist, CD28 activator, TIM3 inhibitor, BTLA inhibitor, TIGIT inhibitor, CD38 inhibitor, CD47 inhibitor, IDO inhibitor, VEGF antagonist, Ang2 inhibitor, TGFβ inhibitor, EGFR inhibitor, VISTA inhibitor, CD40 agonist, CSF1R inhibitor, CCR2 inhibitor, CXCR4 inhibitor, CXCR2 inhibitor, CCR4 inhibitor, CXCL12 inhibitor, agonist for costimulatory receptor, antibody for tumor specific antigen, anti-CD3 / anti-CD20 bispecific antibody, GM-CSF, cytotoxin, chemotherapeutic agent, IL-6R inhibitor, IL-10 inhibitor, oncolytic virus, cytokine, ADC, chimeric antigen receptor T cell, anti-inflammatory drug, NSAID, and dietary supplement. In another embodiment, the pharmaceutical delivery system is for use in treating tumors or inhibiting tumor growth. In another embodiment, the tumor comprises a type 2 immune-dependent cancer.
[0015] In another aspect, the disclosed technology relates to a kit comprising: (a) a pharmaceutical composition comprising an IL-4 / IL-13 pathway inhibitor and a pharma- ceutical acceptable carrier; (b) a pharmaceutical delivery system having a pharmaceutical composition comprising a PD-1 inhibitor and a pharma- ceutical acceptable carrier; and written instructions for using the IL-4 / IL-13 pathway inhibitor in combination with a PD-1 inhibitor to treat or inhibit the growth of a tumor.
[0016] In another aspect, the disclosed technology relates to an IL-4 / IL-13 pathway inhibitor for use in a method of treating or inhibiting the growth of a tumor in combination with a PD-1 inhibitor, the method comprising administering a therapeutically effective amount of each inhibitor to a subject in need thereof. In another aspect, the disclosed technology relates to an IL-4 / IL-13 pathway inhibitor for use in a method of treating or inhibiting the growth of a tumor in combination with a PD-1 inhibitor. With respect to the inhibitors, the methods comprise administering to a subject in need thereof a therapeutically effective amount of each inhibitor. [Brief description of the drawings]
[0017] [Figure 1A] FIG 1A is a line graph showing tumor volume reduction from a baseline tumor volume of 30-110 mm3 according to the study described in Example 1. Asterisks (*) indicate the degree of statistical significance compared to the isotype control (IgG). [Figure 1B] FIG. 1B is a bar graph showing the percent change in tumor volume in individual animals from baseline tumor volumes of 30-110 mm3 to day 38 according to the study described in Example 1. [Figure 2A] Figure 2A is a line graph showing tumor volume reduction from a baseline tumor volume of 50-110 mm3 following the replicate study described in Example 1. Asterisks (*) indicate the degree of statistical significance compared to the isotype control (IgG). [Figure 2B] FIG. 2B is a bar graph showing the percent change in tumor volume in individual animals from a baseline tumor volume of 50-110 mm3 to day 38 according to the replicate study described in Example 1. [Figure 3A] FIG. 3A is a bar graph showing IL-4 and IL-13 mRNA expression compared to normal in Balb / c mice implanted subcutaneously (Sub-Cu) or orthotopically (Ortho) with syngeneic pancreatic tumor organoid cells (KP cells) engineered to express oncogenic KRAS and concomitantly lose function of the P53 tumor suppressor, as described in Example 3. [Figure 3B] FIG. 3B is a bar graph showing IL-4 cytokine production in Balb / c mice implanted subcutaneously (Sub-Cu) or orthotopically (Ortho) with syngeneic pancreatic tumor organoid cells (KP cells) engineered to express oncogenic KRAS with concomitant loss of P53 tumor suppressor function, as described in Example 3. [Figure 4A]4A is a line graph showing tumor volume reduction from a baseline tumor volume of 70-100 mm3 to day 40 according to the study described in Example 4. Asterisks (*) indicate the degree of statistical significance compared to the isotype control (IgG). [Figure 4B] FIG. 4B is a bar graph showing the percent change in tumor volume in individual animals from a baseline tumor volume of 70-100 mm3 to day 40 according to the study described in Example 4. [Figure 4C] FIG. 4C is a pair of bar graphs showing systemic interferon gamma (IFNg) and tumor necrosis factor alpha (TNFa) cytokine levels measured in tumor lysates at the end of the study described in Example 4. [Figure 5A] FIG. 5A is a bar graph showing the percent change in tumor volume in individual animals from a baseline tumor volume of 50-100 mm 3 to the end of the study according to the study described in Example 5. [Figure 5B] FIG. 5B is a bar graph showing hyaluronic acid (HA) content in pancreatic tumors as revealed by histochemical staining method using biotinylated HA binding protein (HABP) for four treatment groups: ISO / ISO, IL-4R / ISO, ISO / PD-1, and IL-4R / PD-1 according to the study described in Example 5. [Figure 5C] FIG. 5C is a bar graph showing CD8+ T cell infiltration within the tumor matrix as represented by histological quantification of the tumor infiltrating lymphocyte (TIL) marker CD8 for four treatment groups: ISO / ISO, IL-4R / ISO, ISO / PD-1, and IL-4R / PD-1, according to the study described in Example 5. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0018] Detailed Description It is to be understood that the methods and experimental conditions may vary, and therefore the present disclosure is not limited to such particular methods and experimental conditions described. The terminology used is for the purpose of describing particular embodiments only and is not intended to be limiting, and the scope of the present disclosure will be limited only by the appended claims.
[0019] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by those skilled in the art to which the disclosed invention belongs.As used herein, when used in reference to a specific stated value, the term "about" means that the value may vary by 1% or less from the stated value.For example, as used herein, the expression "about 100" includes 99 and 101, and all values therebetween (e.g., 99.1, 99.2, 99.3, 99.4, etc.).
[0020] Although any methods and materials similar or equivalent to those described herein can be used in the practice of this disclosure, the preferred methods and materials are now described.
[0021] The present disclosure includes a method of treating cancer comprising administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor in combination with a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor to a subject in need thereof. In some embodiments, the disclosed method targets type 2 immune-dependent pro-tumorigenic mechanisms in cancer, thus providing a new and highly effective method for treating or inhibiting the growth of tumors, including those that exhibit fibrotic features. In some embodiments, the disclosed method treats type 2 immune-dependent cancers using IL-4R blockade or other immunotherapies targeting type 2 immune response pathways in combination with anti-tumor agents, including but not limited to ICBs (e.g., chemotherapy, bispecific antibodies, antibody drug conjugates (ADCs), and chimeric antigen receptor (CAR) T cells).
[0022] As used herein, a "type 2 immune gene gene signature" refers to the upregulation or overexpression of one or more type 2 cytokines, type 2 chemokines, type 2 receptors, and type 2 downstream target genes, including IL-13RA2, IL25, IL17RB, SERPINB2, CCL24, CEACAM1, CCL1, MUC5B, CCL26, IL-13RA1, POSTN, IL6R, CCL18, CCL17, FCER2, CCR3, IL6, CCL8, CRLF2, IL33, TSLP, IL-4R, CCR4, PTGDR, FCER1A, IL1RL1, DPP4, IL-4, IL5, and IL-13. As demonstrated in Example 3, for example, IL-4 and IL-13 gene expression was found to be significantly upregulated in an in vivo model of pancreatic cancer, a type 2 immune-dependent cancer.
[0023] As used herein, "type 2 immune dependent cancer" refers to a cancer or a subset of cancers, such as a human cancer or a subset of human cancers, that exhibits a strong type 2 immune gene signature.
[0024] As used herein, "type 2 immune pathway blockade" refers to immunotherapy that targets any gene in the type 2 immune gene signature.
[0025] Methods of Treating or Inhibiting Tumor Growth - Patent application The present disclosure includes a method for treating, ameliorating, or reducing the severity of at least one symptom or sign of cancer, or inhibiting the growth of cancer in a subject. In this embodiment, the disclosed method includes selecting a subject having a tumor and administering to the subject a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4 antibody, an anti-IL-13 antibody, an anti-IL-4 / IL-13 bispecific antibody, an IL-4 receptor (IL-4R) inhibitor, an anti-IL-4R antibody, or any other "IL-4 / IL-13 pathway inhibitor" as described herein. The present invention includes administering to a subject in need thereof a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor (e.g., an antibody that specifically binds PD-1, PD-L1, and / or PD-L2, or any other "PD-1 inhibitor" described herein).
[0026] In this disclosure, reference to any particular anti-IL-4R antibody and / or any particular anti-PD-1 antibody is provided to illustrate a representative IL-4 / IL-13 pathway inhibitor and a representative PD-1 inhibitor, respectively, and does not limit the scope of the disclosure, as other combinations of IL-4 / IL-13 pathway inhibitors and PD-1 inhibitors may also be used.
[0027] As used herein, the terms "treating," "treat," or the like refer to alleviating or reducing the severity of at least one symptom or sign, eliminating the causal role of the symptom, either temporarily or permanently. By "tumor," it is meant to slow or inhibit tumor growth, reduce tumor cell mass or tumor burden or promote tumor regression, cause tumor shrinkage, necrosis and / or disappearance, prevent tumor recurrence, prevent or inhibit metastasis, inhibit metastatic tumor growth, eliminate the need for surgery, shrink tumors to facilitate surgery, increase resection rates, and / or increase the survival of a subject. In many embodiments, the terms "tumor," "cancer," and "malignant tumor" are used interchangeably and refer to one or more growths.
[0028] In some embodiments, the tumor comprises a type 2 immune-dependent cancer. Examples of type 2 immune-dependent cancers include, but are not limited to, pancreatic cancer (e.g., PDAC), breast cancer, colorectal cancer, ovarian cancer, lung cancer, lymphoma, and bladder cancer.
[0029] As used herein, the phrase "subject in need thereof" refers to a human or non-human mammal exhibiting one or more symptoms or signs of cancer, and / or a human or non-human mammal diagnosed with cancer, including solid tumors, and in need of treatment for the above. In many embodiments, the terms "subject" and "patient" are used interchangeably. The methods disclosed herein may include a step of selecting a subject in need thereof. For example, a human subject may have been diagnosed with a primary or metastatic tumor and / or one or more symptoms or signs including, but not limited to, enlarged lymph nodes, enlarged abdomen, chest pain / tightness, unexplained weight loss, fever, night sweats, persistent fatigue, loss of appetite, enlarged spleen, itching. The phrase includes a subject having a primary tumor, an established tumor, or a recurrent tumor. In certain embodiments, the phrase includes a human subject having a solid tumor and / or in need of treatment for a solid tumor. In other embodiments, the phrase includes a human subject having a hemolytic tumor (e.g., lymphoma or leukemia) and / or in need of treatment for a hemolytic tumor. The term also includes subjects with primary or metastatic tumors (advanced malignancies). The term also includes subjects with tumors, including type 2 immune-dependent cancers, including, but not limited to, pancreatic cancer, non-small cell lung cancer, squamous cell lung cancer, and Hodgkin's lymphoma.
[0030] In certain embodiments, the phrase includes patients having tumors that are resistant or refractory to or inadequately controlled by conventional therapy (e.g., treatment with IL-4 / IL-13 pathway inhibitor monotherapy, PD-1 inhibitor monotherapy, anti-cancer agents such as carboplatin, or docetaxel). In certain embodiments, the phrase includes patients having tumors that have been treated with one or more lines of conventional therapy (e.g., surgically resected) but have subsequently recurred. In certain embodiments, the phrase includes subjects having tumors that are not candidates for therapeutic surgery or therapeutic radiation, or for which conventional anti-cancer therapy is not advisable, e.g., due to toxic side effects.
[0031] In other embodiments, the phrase "subject in need thereof" includes patients with malignant tumors that have been treated but have subsequently recurred or metastasized. For example, a patient with a tumor may have been treated with one or more anti-cancer drugs that resulted in tumor regression; however, the patient subsequently recurs with a cancer that is resistant to the one or more anti-cancer drugs (e.g., chemotherapy-resistant cancer) and can be treated with the methods of the present disclosure. In certain embodiments, the phrase includes patients who exhibit upregulation of at least one cytokine, such as IL-4 and / or IL-13. In certain embodiments, the phrase includes patients who exhibit increased production of at least one cytokine, such as increased production of IL-4. In certain embodiments, the phrase includes patients who exhibit increased hyaluronic acid (HA) content in tumors.
[0032] According to certain embodiments, the disclosure includes methods for treating, slowing or inhibiting tumor growth. In certain embodiments, the disclosure includes methods for promoting tumor regression. In certain embodiments, the disclosure includes methods for reducing tumor cell mass or reducing tumor burden. In certain embodiments, the disclosure includes methods for increasing survival, increasing response or increasing duration of response in a treated subject. In some embodiments, the disclosure includes methods for treating or inhibiting tumor growth in a subject with pancreatic cancer, breast cancer, colorectal cancer, brain cancer, skin cancer, renal cancer, ovarian cancer, lung cancer (e.g., non-small cell lung cancer), Hodgkin's lymphoma, or bladder cancer.
[0033] In some embodiments, the disclosed methods include administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor in combination with an additional therapeutic agent or treatment (e.g., regimen or procedure). In certain embodiments, the disclosed methods include administering an additional therapeutic agent, such as an anti-cancer drug. As used herein, "anti-cancer drug" refers to any agent useful for treating cancer, including, but not limited to, cytotoxins and agents such as antimetabolites, alkylating agents, anthracyclines, antibiotics, mitotic inhibitors, procarbazine, hydroxyurea, asparaginase, corticosteroids, mytotane (O,P'-(DDD)), biologics (e.g., antibodies and interferons), and radioactive agents. As used herein, "cytotoxins or cytotoxic agents" also refers to chemotherapeutic agents and refers to any agent that is detrimental to cells. Examples include Taxol® (paclitaxel), temozolamide, cytochalasin B, gramicidin D, ethidium bromide, emetine, cisplatin, mitomycin, etoposide, tenoposide, vincristine, vinbiastine, coichicin, doxorubicin, daunorubicin, dihydroxy anthracin dione, mitoxantrone, mithramycin, actinomycin D, 1-dehydrotestosterone, glucocorticoids, procaine, tetracaine, lidocaine, propranolol, and puromycin, as well as analogs or homologs thereof. Additional therapeutic agents or treatments may be administered to increase anti-tumor efficacy, to reduce toxic effects of one or more therapies, and / or to reduce the dosage of one or more therapies.In various embodiments, the additional therapeutic agent or treatment is: chemotherapy, cyclophosphamide, surgery, radiation, a cancer vaccine, lymphocyte-activation gene 3 (LAG3) inhibitors (e.g., anti-LAG3 antibodies), cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) inhibitors (e.g., ipilimumab), glucocorticoid-inducible tumor necrosis factor receptor (GITR) agonists (e.g., anti-GITR antibodies), T-cell immunoglobulin and mucin-containing-3 (TIM3) inhibitors, B and T lymphocyte attenuator (BTLA) inhibitors, T cell immunoreceptor with Ig and ITIM domains (TIGIT) inhibitors, CD47 inhibitors, in. dolamine-2,3-dioxygenase (IDO) inhibitors, vascular endothelial growth factor (VEGF) antagonists (e.g., "VEGF-traps" such as aflibercept or other VEGF-inhibitory fusion proteins as set forth in US 7,087,411, or anti-VEGF antibodies or antigen-binding fragments thereof (e.g., bevacizumab, or ranibizumab) or small molecule kinase inhibitors of VEGF receptors (e.g., sunitinib, sorafenib, or pazopanib)), angiopoietin-2 (Ang2) inhibitors (e.g., nesvacumab), transforming growth factor beta (TGFβ) inhibitors, epidermal growth factor receptor (EGFR) inhibitors (e.g., erlotinib, cetuximab), agonists for costimulatory receptors (e.g., agonists for CD28), VISTA inhibitors agents, CD38 inhibitors, CD40 agonists, CSF1R inhibitors, CCR2 inhibitors, CXCR4 inhibitors, CXCR2 inhibitors, CCR4 inhibitors, CXCL12 inhibitors, antibodies against tumor-specific antigens [e.g., CA9, CA125, melanoma-associated antigen 3 (MAGE3), carcinoembryonic antigen (CEA), vimentin, tumor-M2-PK, prostate-specific antigen (PSA), mucin-1, MART-1, and CA19-9], anti-CD3 / anti-CD20 bispecific antibodies, vaccines (e.g., Bacillus Calmette-Guerin), granulocyte-macrophage colony-stimulating factor (GM-CSF), cytotoxins, chemotherapeutic agents, IL-6R inhibitors (e.g., sarilumab), IL-10 inhibitors, cytokines such as IL-2, IL-7, IL-12, IL-21, and IL-15, antibody-drug conjugates (ADCs) (e.g., anti-CD19-DM4 ADC, and anti-DS6-DM4 ADC), oncolytic viruses, chimeric antigen receptor T cells (e.g., CD19-targeted T cells), anti-inflammatory drugs such as corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), and nutritional supplements such as antioxidants.
[0034] In certain embodiments, the IL-4 / IL-13 pathway inhibitor and the PD-1 inhibitor may be administered in combination with treatments including chemotherapeutic agents (e.g., dacarbazine, temozolomide, cyclophosphamide, docetaxel, doxorubicin, daunorubicin, cisplatin, carboplatin, gemcitabine, methotrexate, mitoxantrone, oxaliplatin, paclitaxel, and vincristine) and / or surgery. In certain embodiments, the IL-4 / IL-13 pathway inhibitor and the PD-1 inhibitor may be administered in combination with anti-tumor therapy, including, but not limited to, chemotherapy, radiation, surgery, or conventional anti-tumor therapy as described elsewhere herein.
[0035] In certain embodiments, the disclosed methods result in increased inhibition of tumor growth - e.g., more tumor regression in treated subjects. For example, the disclosed methods of administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor promote at least about 10%, about 20%, about 30%, about 40%, about 50%, about 60%, about 70%, or about 80% more tumor regression in treated subjects compared to untreated subjects or subjects treated with either inhibitor as monotherapy.
[0036] In certain embodiments, the disclosed methods of administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor result in a delay in tumor growth and tumor incidence, for example, tumor growth can be delayed by about 3 days, more than 3 days, about 7 days, more than 7 days, more than 15 days, more than 1 month, more than 3 months, more than 6 months, more than 1 year, more than 2 years, or more than 3 years in treated subjects compared to untreated subjects or subjects treated with either inhibitor as monotherapy.
[0037] In certain embodiments, the disclosed methods of administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor result in the complete disappearance of all evidence of tumor cells (a "complete response"), a reduction of at least 30% or more in tumor cells or tumor size (a "partial response"), or a complete or partial disappearance of tumor cells, including new measurable tumors. Tumor reduction can be achieved by any of the methods known in the art. It can be measured by methods such as X-ray, positron emission tomography (PET), computed tomography (CT), magnetic resonance imaging (MRI), cytology, histology, or molecular genetic analysis.
[0038] In certain embodiments, the disclosed methods of administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor result in increased overall survival (OS) or progression-free survival (PFS) of a subject compared to subjects receiving a "standard of care" (SOC) therapy (e.g., chemotherapy, surgery, or radiation). In certain embodiments, PFS is increased by at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 1 year, at least 2 years, or at least 3 years compared to subjects receiving any one or more SOC therapies. In certain embodiments, OS is increased by at least 1 month, at least 2 months, at least 3 months, at least 4 months, at least 5 months, at least 6 months, at least 7 months, at least 8 months, at least 9 months, at least 10 months, at least 11 months, at least 1 year, at least 2 years, or at least 3 years compared to subjects receiving any one or more SOC therapies.
[0039] In certain embodiments, the disclosed methods of administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor result in, for example, greater than 2%, greater than 3%, greater than 4%, greater than 5%, greater than 6%, greater than 7%, greater than 8%, greater than 9%, greater than 10%, greater than 20%, greater than 30%, greater than 40%, or greater than 50% increased response and increased duration of response in treated subjects compared to untreated subjects or subjects treated with either inhibitor as monotherapy.
[0040] In certain embodiments, the combination of inhibitors administered is safe and well-tolerated by the subject such that there is no increase in adverse side effects compared to subjects treated with either inhibitor as a monotherapy.
[0041] In certain embodiments, the disclosed methods include administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor to a subject, wherein the subject exhibits upregulation of at least one cytokine, such as IL-4 and / or IL-13. In some embodiments, the subject exhibits greater upregulation of at least one cytokine (e.g., IL-4 and / or IL-13) compared to a subject not in need of anti-tumor treatment.
[0042] In certain embodiments, the disclosed methods include administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor to a subject, where the subject exhibits increased production of at least one cytokine, such as increased production of IL-4. In some embodiments, the subject exhibits increased production of at least one cytokine (e.g., IL-4) compared to a subject not in need of anti-tumor treatment.
[0043] In certain embodiments, the disclosed methods of administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor result in significantly increased production of interferon gamma (IFNg) compared to subjects treated with either inhibitor as monotherapy. In some such embodiments, these disclosed methods further result in enhanced tumor regression and anti-tumor activity.
[0044] In certain embodiments, the disclosed methods include administering to a subject a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor, wherein the subject: In some such embodiments, the subject exhibits increased hyaluronic acid (HA) content in the tumor, hi some such embodiments, the subject exhibits higher HA content than subjects who do not have type 2 immune-dependent cancer.
[0045] In certain embodiments, the disclosed methods of administering to a subject a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor result in a reduction in hyaluronic acid (HA) content in tumors.
[0046] In certain embodiments, the disclosed methods of administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a PD-1 inhibitor to a subject result in significantly increased densities of tumor infiltrating lymphocytes (TILs), thereby enhancing the cytotoxic anti-tumor efficacy of the combination therapy. In some such embodiments, these disclosed methods further result in enhanced tumor regression and anti-tumor activity.
[0047] IL-4 / IL-13 pathway inhibitors The methods disclosed herein include administering a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor to a subject in need thereof. As used herein, an "IL-4 / IL-13 pathway inhibitor" (also referred to herein as an "IL-4 / IL-13 pathway antagonist", "IL-4 / IL-13 pathway blocker", etc.) is any agent that inhibits or attenuates at least one of: (i) the binding of IL-4 and / or IL-13 to their respective receptors; (ii) IL-4 and / or IL-13 signaling and / or activity; and / or (iii) downstream signaling / activity resulting from the binding of IL-4 and / or IL-13 to their respective receptors. Exemplary IL-4 / IL-13 pathway inhibitors include, but are not limited to, anti-IL-4 antibodies (e.g., those disclosed in U.S. Pat. No. 7,740,843, and U.S. Patent Application Publication Nos. 20100297110, 20160207995), anti-IL-13 antibodies (e.g., those disclosed in U.S. Pat. Nos. 7,501,121, 7,674,459, 7,807,788, 7,910708, 7,915,388, 7,935,343, 8,088,618, 8,691,233, No. 9605065, U.S. Patent Application Publication Nos. 20060073148, 20080044420, and EP2627673B1), bispecific antibodies that bind IL-4 and IL-13 (e.g., antibodies disclosed in U.S. Patent Application Publication Nos. 8,388,965, U.S. Patent Application Publication Nos. 20110008345, 20130251718, and 20160207995), and IL-4 receptor (IL-4R) inhibitors (described below). The portions of the publications cited herein that identify IL-4 / IL-13 pathway inhibitors are hereby incorporated by reference.
[0048] In some embodiments, the IL-4 / IL-13 pathway inhibitor can be an antibody, a small molecule compound, a nucleic acid, a polypeptide, or a functional fragment or variant thereof. Non-limiting examples of suitable IL-4 / IL-13 pathway inhibitor antibodies include anti-IL-4 antibodies, anti-IL-13 antibodies, and anti-IL-4 / IL-13 bispecific antibodies, anti-IL-4R antibodies, and antigen-binding fragments of any of the foregoing. Other non-limiting examples of suitable IL-4 / IL-13 pathway inhibitors include: RNAi molecules, such as anti-IL-4 RNAi molecules and anti-IL-13 RNAi molecules, antisense molecules, such as anti-IL-4 antisense RNA and anti-IL-13 antisense RNA, and dominant negative proteins, such as dominant negative IL-4 proteins, dominant negative IL-13 proteins.
[0049] As used herein, an "IL-4R inhibitor" (also referred to herein as an "IL-4 / IL-13 pathway inhibitor", "IL-4Rα antagonist", "IL-4R blocker", "IL-4Rα blocker", etc.) refers to an agent that binds to IL-4Rα or an IL-4R ligand. The IL-4R inhibitor is any agent that interacts with or inhibits or attenuates the normal biological signaling function type 1 and / or type 2 IL-4 receptor. Type 1 IL-4 receptor is a dimeric receptor that includes IL-4Rα chain and γc chain. Type 2 IL-4 receptor is a dimeric receptor that includes IL-4Rα chain and IL-13Rα1 chain. Type 1 IL-4 receptor interacts and stimulates with IL-4, whereas type 2 IL-4 receptor interacts and stimulates with both IL-4 and IL-13. Thus, the IL-4R inhibitor that can be used in the disclosed method can function by blocking IL-4-mediated signaling, IL-13-mediated signaling, or both IL-4 and IL-13-mediated signaling. Thus, the IL-4R inhibitor of the present disclosure can prevent the interaction of IL-4 and / or IL-13 with type 1 or type 2 receptor.
[0050] Non-limiting examples of categories of IL-4R inhibitors include IL-4 muteins (e.g., pitrakinra), small molecule IL-4R inhibitors, anti-IL-4R aptamers, peptide-based IL-4R inhibitors (e.g., "peptibody" molecules), "receptor-bodies" (e.g., engineered molecules that contain the ligand-binding domain of an IL-4R component), and antibodies or antigen-binding fragments of antibodies that specifically bind to human IL-4Rα. As used herein, IL-4R inhibitors also include antigen-binding proteins that specifically bind to IL-4 and / or IL-13.
[0051] Other non-limiting examples of suitable IL-4 / IL-13 pathway inhibitors that can be used in the context of the present disclosure include, for example, pitrakinra (AER-001; BAY-16-9996), aeroderm (AER-003), and antibodies known in the art as dupilumab, pascolizumab, AMG-317, MILR1444A, CAT-354, QAX576, anrukinzumab (IMA-638), ISIS-369645 (AIR-645), IMA-026, APG-201, CNTO-607, MK-6105, MEDI9314, MEDI2045, tralokinumab, lebrikizumab, romilkimab, and DOM-0910.
[0052] Anti-IL-4Rα antibodies and antigen-binding fragments thereof According to certain exemplary embodiments of the present disclosure, the IL-4 / IL-13 pathway inhibitor is an anti-IL-4Rα antibody or an antigen-binding fragment thereof. The term "antibody" as used throughout this disclosure includes immunoglobulin molecules comprising four polypeptide chains (two heavy (H) chains and two light (L) chains) interconnected by disulfide bonds, as well as multimers thereof (e.g., IgM). In a typical antibody, each heavy chain comprises a heavy chain variable region (referred to herein as HCVR or V H The heavy chain constant region is made up of three domains, C H 1. C H 2 and C HEach light chain comprises a light chain variable region (referred to herein as LCVR or V L The light chain constant region comprises one domain (C L 1) is included. H and V L The regions can be further subdivided into regions of hypervariability, termed complementarity determining regions (CDRs), interspersed with more conserved regions, termed framework regions (FRs). H and V L is composed of three CDRs and four FRs arranged from amino-terminus to carboxy-terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4. In different embodiments of the present disclosure, the FRs of the antibody (or antigen-binding portion thereof) may be identical to human germline sequences or may be naturally or artificially modified. An amino acid consensus sequence may be defined based on a side-by-side analysis of two or more CDRs.
[0053] The term "antibody" as used throughout this disclosure includes antigen-binding fragments thereof, i.e., antigen-binding fragments of a complete antibody molecule. The terms "antigen-binding portion" of an antibody, "antigen-binding fragment" of an antibody, and the like, as used throughout this disclosure, refer to any naturally occurring, enzymatically obtainable, synthetic, or other antibody that specifically binds to an antigen to form a complex. includes engineered polypeptides or glycoproteins. Antigen-binding fragments of antibodies can be derived, for example, from intact antibody molecules using any suitable standard technique, such as proteolytic digestion or recombinant genetic engineering techniques including the manipulation and expression of DNA encoding antibody variable domains and optionally constant domains. Such DNA is known and / or readily available, for example, from commercial sources, DNA libraries (including, for example, phage-antibody libraries), or can be synthesized. The DNA can be, for example, sequenced and engineered using chemical or molecular biology techniques to place one or more variable and / or constant domains in the appropriate configuration, or to introduce codons, generate cysteine residues, modify, charge or delete amino acids, etc.
[0054] Non-limiting examples of antigen-binding fragments include: (i) Fab fragments; (ii) F(ab')2 fragments; (iii) Fd fragments; (iv) Fv fragments; (v) single chain Fv (scFv) molecules; (vi) dAb fragments; and (vii) minimal recognition units consisting of amino acid residues that mimic hypervariable regions of an antibody (e.g., isolated complementarity determining regions (CDRs) such as CDR3 peptides), or constrained FR3-CDR3-FR4 peptides. Other engineered molecules, such as domain-specific antibodies, single domain antibodies, domain deleted antibodies, chimeric antibodies, CDR-grafted antibodies, bispecific antibodies, trispecific antibodies, tetraspecific antibodies, minibodies, nanobodies (e.g., monovalent nanobodies, bivalent nanobodies, etc.), small modular immunopharmaceuticals (SMIPs), and shark variable IgNAR domains, are also encompassed within the expression "antigen-binding fragment" as used throughout this disclosure.
[0055] Antigen-binding fragments of antibodies typically contain at least one variable domain. The variable domain may be of any size or amino acid composition and generally contains at least one CDR adjacent to or in frame with one or more framework sequences. LDomain and Related V H In an antigen-binding fragment having a domain, H and V L The domains can be positioned in any suitable arrangement relative to each other. For example, the variable region is a dimer and the V H -V H , V H -V L Or V L -V L Alternatively, the antigen-binding fragment of the antibody may contain a monomeric V H Or V L It may contain domains.
[0056] In certain embodiments, an antigen-binding fragment of an antibody may contain at least one variable domain covalently linked to at least one constant domain. Non-limiting exemplary configurations of variable and constant domains that may be found in an antigen-binding fragment of an antibody of the present disclosure include: (i) a V H -C H 1;(ii)V H -C H 2;(iii)V H -C H 3;(iv)V H -C H 1-C H 2;(v)V H -C H 1-C H 2-C H 3;(vi)V H -C H 2-C H 3;(vii)V H -C L ;(viii)V L -C H 1;(ix)V L -C H 2;(x)V L -C H 3;(xi)V L -C H 1-C H 2;(xii)V L -C H 1-C H 2-C H 3;(xiii)VL -C H 2-C H 3; and (xiv) V L -C L In any configuration of variable and constant domains, including any of the exemplary configurations listed above, the variable and constant domains may be directly linked to each other or may be linked by a complete or partial hinge or linker region. A hinge region may consist of at least two (e.g., 5, 10, 15, 20, 40, 60 or more) amino acids that create a flexible or semi-flexible linkage between adjacent variable and / or constant domains in a single polypeptide molecule. Additionally, antigen-binding fragments of antibodies of the present disclosure may be linked to each other and / or to one or more monomeric V H Or V L The domains may comprise homodimers or heterodimers (or other multimers) of any of the variable and constant domain configurations listed above non-covalently associated (e.g., by disulfide bonds).
[0057] The term "antibody" as used throughout this disclosure also includes multispecific (e.g., bispecific) antibodies. Multispecific antibodies or antigen-binding fragments of antibodies typically contain at least two different variable domains, where each variable domain can specifically bind to a separate antigen or to a different epitope on the same antigen. Any multispecific antibody format can be adapted for use in the context of the antibodies or antigen-binding fragments of antibodies of the present disclosure using conventional techniques available in the art. For example, the present disclosure includes methods that include the use of bispecific antibodies, where one arm of the immunoglobulin is specific for IL-4Rα or a fragment thereof, and the other arm of the immunoglobulin is specific for a second therapeutic target or is conjugated with a therapeutic moiety. Exemplary bispecific formats that can be used in the context of the present disclosure include, but are not limited to, for example, scFv-based bispecific formats or diabody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, Quadroma, knob-into-hole, common light chain (e.g., common light chain with knob-into-hole), CrossMab, CrossFab, (SEED) body, leucine zipper, Duobody, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab 2 Bispecific formats include (for a review of the aforementioned formats, see, e.g., Klein et al. 2012, mAbs 4(6):653-663, and references cited therein). Bispecific antibodies can also be constructed using peptide / nucleic acid conjugates, for example, where unnatural amino acids with orthogonal chemical reactivity are used to generate site-specific antibody-oligonucleotide linkages that then self-assemble into multimeric complexes with defined composition, valency, and configuration. (See, e.g., Kazane et al., J. Am. Chem.Soc., 2013, 135(1):340-46).
[0058] The antibody used in the method of the present disclosure may be a human antibody. The term "human antibody" as used throughout this disclosure is intended to include antibodies having variable and constant domains derived from human germline immunoglobulin sequences. Nevertheless, the human antibody of the present disclosure may contain amino acid residues not encoded by human germline immunoglobulin sequences, for example in the CDRs, particularly in CDR3 (e.g., mutations introduced by random or site-specific mutagenesis in vitro or somatic mutation in vivo). However, the term "human antibody" as used throughout this disclosure is not intended to include antibodies in which CDR sequences derived from the germline of another mammalian species, such as a mouse, have been grafted onto human framework sequences.
[0059] The antibody used in the methods of the present disclosure may be a recombinant human antibody. The term "recombinant human antibody" as used throughout this disclosure is intended to include all human antibodies that are produced, expressed, generated or isolated by recombinant means, such as antibodies expressed using a recombinant expression vector transfected into a host cell (described further below), antibodies isolated from a recombinant combinatorial human antibody library (described further below), antibodies isolated from an animal (e.g., a mouse) that is transgenic for human immunoglobulin genes (e.g., Taylor et al. (1992) Nucl. Acids Res., 20:6287-6295), or antibodies produced, expressed, generated or isolated by any other means, including splicing human immunoglobulin gene sequences with other DNA to the sequences. Such recombinant human antibodies have variable and constant regions derived from human germline immunoglobulin sequences. However, in certain embodiments, such recombinant human antibodies are subjected to in vitro mutagenesis (or, when animals transgenic for human Ig sequences are used, in vivo somatic mutagenesis) to thereby improve the V H and V L The amino acid sequence of the region is H and V LThese are sequences that are derived from and related to sequences, but that may not naturally occur within the human antibody germline repertoire in vivo.
[0060] According to certain embodiments, the antibody used in the methods of the present disclosure specifically binds to IL-4Rα. The term "specifically binds" or the like means that the antibody or antigen-binding fragment thereof forms a complex with the antigen that is relatively stable under physiological conditions. Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, as used in the context of this disclosure, an antibody that "specifically binds" to IL-4Rα has a K of less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM for IL-4Rα or a portion thereof, as measured in a surface plasmon resonance assay. D However, an isolated antibody that specifically binds human IL-4Rα may have cross-reactivity to other antigens, such as IL-4Rα molecules from other (non-human) species.
[0061] According to certain exemplary embodiments of the present disclosure, the IL-4 / IL-13 pathway inhibitor is an anti-IL-4Rα antibody or antigen-binding fragment thereof comprising a heavy chain variable region (HCVR), a light chain variable region (LCVR), and / or a complementarity determining region (CDR) comprising any of the amino acid sequences of the anti-IL-4R antibodies set forth in U.S. Patent No. 7,608,693. In certain exemplary embodiments, the anti-IL-4Rα antibody or antigen-binding fragment thereof that can be used in the context of the methods of the present disclosure comprises a heavy chain complementarity determining region (HCDR) of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and a light chain complementarity determining region (LCDR) of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2. According to certain embodiments, the anti-IL-4Rα antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), where HCDR1 comprises the amino acid sequence of SEQ ID NO:3; HCDR2 comprises the amino acid sequence of SEQ ID NO:4; HCDR3 comprises the amino acid sequence of SEQ ID NO:5; LCDR1 comprises the amino acid sequence of SEQ ID NO:6; LCDR2 comprises the amino acid sequence of SEQ ID NO:7; and LCDR3 comprises the amino acid sequence of SEQ ID NO:8. In yet other embodiments, the anti-IL-4R antibody or antigen-binding fragment thereof comprises a HCVR comprising SEQ ID NO:1 and a LCVR comprising SEQ ID NO:2. In certain embodiments, the methods of the disclosure comprise the use of an anti-IL-4R antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9. In some embodiments, the anti-IL-4R antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:10. An exemplary antibody comprising a HCVR comprising the amino acid sequence of SEQ ID NO:1 and a LCVR comprising the amino acid sequence of SEQ ID NO:2 is the fully human anti-IL-4R antibody known as dupilumab (DUPIXENT®). According to certain exemplary embodiments, the methods of the present disclosure include the use of dupilumab, or a biological equivalent thereof.The term "bioequivalent" with respect to dupilumab refers to an anti-IL-4R antibody or IL-4R binding protein or fragment thereof that is a pharmaceutical equivalent or pharmaceutical substitute having a rate and / or extent of absorption that does not differ significantly from that of dupilumab when administered in either single or multiple doses under similar experimental conditions at the same molar dose. In the context of the present disclosure, the term refers to antigen-binding proteins that bind to IL-4R that do not have clinically meaningful differences from dupilumab in their safety, purity and / or potency.
[0062] According to certain embodiments of the present disclosure, the anti-human IL-4R antibody or antigen-binding fragment thereof comprises a HCVR having 90%, 95%, 98% or 99% sequence identity to SEQ ID NO:1.
[0063] According to a specific embodiment of the present disclosure, an anti-human IL-4R antibody or an antigen-binding fragment thereof is The compounds include an LCVR having 90%, 95%, 98% or 99% sequence identity to SEQ ID NO:2.
[0064] According to certain embodiments of the present disclosure, the anti-human IL-4R antibody or antigen-binding fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 1 with no more than 5 amino acid substitutions. According to certain embodiments of the present disclosure, the anti-human IL-4R antibody or antigen-binding fragment thereof comprises a LCVR comprising the amino acid sequence of SEQ ID NO: 2 with no more than 2 amino acid substitutions.
[0065] Sequence identity can be measured by methods known in the art (eg, GAP, BESTFIT, and BLAST).
[0066] The present disclosure also includes the use of anti-IL-4R antibodies in methods for treating cancer, wherein the anti-IL-4R antibodies comprise variants of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein having one or more conservative amino acid substitutions. For example, the present disclosure includes the use of anti-IL-4R antibodies having HCVR, LCVR and / or CDR amino acid sequences that include, for example, 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc., conservative amino acid substitutions compared to any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein.
[0067] Other anti-IL-4Rα antibodies that can be used in the context of the methods of the present disclosure include, for example, the antibody known in the art as AMG317 (Corren et al., 2010, Am J Respir Crit Care Med., 181(8):788-796), or MEDI9314, or any of the anti-IL-4Rα antibodies set forth in U.S. Pat. Nos. 7,186,809, 7,605,237, 7,638,606, 8,092,804, 8,679,487, or 8,877,189. The portions of the publications cited herein that identify anti-IL-4Rα antibodies are hereby incorporated by reference.
[0068] Anti-IL-4Rα antibodies used in the context of the methods of the present disclosure may have pH-dependent binding characteristics. For example, anti-IL-4Rα antibodies for use in the methods of the present disclosure may exhibit decreased binding to IL-4Rα at acidic pH compared to neutral pH. Alternatively, anti-IL-4Rα antibodies of the present disclosure may exhibit enhanced binding to their antigen at acidic pH compared to neutral pH. The expression "acidic pH" includes pH values less than about 6.2, such as about 6.0, 5.95, 5.9, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0 or lower. As used throughout this disclosure, the expression "neutral pH" refers to a pH of about 7.0 to about 7.4. The expression "neutral pH" includes pH values of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.
[0069] In certain instances, "decreased binding to IL-4Rα at acidic pH compared to neutral pH" refers to the K D Value vs. K for antibody binding to IL-4Rα at neutral pH D For example, an antibody or antigen-binding fragment thereof may be expressed in terms of a ratio of values such that the antibody or antigen-binding fragment thereof has an acidic / neutral K of about 3.0 or greater. D When a ratio is presented, it may be considered to indicate "decreased binding to IL-4Rα at acidic pH compared to neutral pH" for the purposes of this disclosure. In certain exemplary embodiments, the acidic / neutral K D The ratios are approximately 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 20.0, 25.0 , 30.0, 40.0, 50.0, 60.0, 70.0, 100.0, or more.
[0070] Antibodies with pH-dependent binding characteristics can be obtained, for example, by screening a population of antibodies for decreased (or enhanced) binding to a particular antigen at acidic pH compared to neutral pH. Furthermore, modifications of the antigen-binding domain at the amino acid level can result in antibodies with pH-dependent characteristics. For example, by replacing one or more amino acids in the antigen-binding domain (e.g., within the CDRs) with histidine residues, an antibody with decreased antigen binding at acidic pH compared to neutral pH can be obtained. As used throughout this disclosure, the expression "acidic pH" refers to a pH of 6.0 or lower.
[0071] PD-1 inhibitors The methods disclosed herein include administering a therapeutically effective amount of a PD-1 inhibitor to a subject in need thereof. As used herein, a "PD-1 inhibitor" refers to any molecule capable of inhibiting, blocking, suppressing or interfering with the activity or expression of PD-1. In some embodiments, the PD-1 inhibitor may be an antibody, a small molecule compound, a nucleic acid, a polypeptide, or a fragment or variant thereof. Non-limiting examples of suitable PD-1 inhibitor antibodies include anti-PD-1 antibodies and antigen-binding fragments thereof, anti-PD-L1 antibodies and antigen-binding fragments thereof, and anti-PD-L2 antibodies and antigen-binding fragments thereof. Other non-limiting examples of suitable PD-1 inhibitors include RNAi molecules, such as anti-PD-1 RNAi molecules, anti-PD-L1 RNAi, and anti-PD-L2 RNAi, antisense molecules, such as anti-PD-1 antisense RNA, anti-PD-L1 antisense RNA, and anti-PD-L2 antisense RNA, and dominant negative proteins, such as dominant negative PD-1 proteins, dominant negative PD-L1 proteins, and dominant negative PD-L2 proteins. Some examples of the aforementioned PD-1 inhibitors are described, for example, in US 9308236, US 10011656, and US No. 20170290808 (the portions identifying PD-1 inhibitors are incorporated herein by reference).
[0072] Anti-PD-1 antibodies and antigen-binding fragments thereof In some embodiments, the PD-1 inhibitor used in the methods disclosed herein is an antibody or antigen-binding fragment that specifically binds to PD-1.
[0073] The terms "antibody," "antigen-binding fragment," "human antibody," "recombinant antibody," and other related terms are defined above. In the context of anti-PD-1 antibodies and antigen-binding fragments thereof, the present disclosure includes the use of bispecific antibodies, in which one arm of the immunoglobulin is specific for PD-1 or a fragment thereof, and the other arm of the immunoglobulin is specific for a second therapeutic target or is linked to a therapeutic moiety. Exemplary bispecific formats that can be used in the context of the present disclosure include, but are not limited to, scFv-based or bispecific antibody bispecific formats, IgG-scFv fusions, dual variable domain (DVD)-Ig, Quadroma, knob-into-hole, common light chain (e.g., common light chain with knob-into-hole), CrossMab, CrossFab, (SEED) body, leucine zipper, Duobody, IgG1 / IgG2, dual acting Fab (DAF)-IgG, and Mab. 2 Bispecific formats include those described herein (for a review of the aforementioned formats, see, e.g., Klein et al. 2012, mAbs 4(6):653-663, and references cited therein). Bispecific antibodies can also be constructed using peptide / nucleic acid linkages, for example, where unnatural amino acids with orthogonal chemical reactivity are used to generate site-specific antibody-oligonucleotide conjugates that then self-assemble into multimeric complexes with defined composition, valency, and configuration (see, e.g., Kazane et al., J. Am. Chem. Soc., 2013, 135). (1):340-46).
[0074] The term "specifically binds" or the like means that an antibody or antigen-binding fragment thereof forms a complex with an antigen that is relatively stable under physiological conditions. Methods for determining whether an antibody specifically binds to an antigen are well known in the art and include, for example, equilibrium dialysis, surface plasmon resonance, and the like. For example, an antibody that "specifically binds" to PD-1 as used in the context of the present disclosure has a K of less than about 500 nM, less than about 300 nM, less than about 200 nM, less than about 100 nM, less than about 90 nM, less than about 80 nM, less than about 70 nM, less than about 60 nM, less than about 50 nM, less than about 40 nM, less than about 30 nM, less than about 20 nM, less than about 10 nM, less than about 5 nM, less than about 4 nM, less than about 3 nM, less than about 2 nM, less than about 1 nM, or less than about 0.5 nM as measured in a surface plasmon resonance assay. D An isolated antibody that specifically binds human PD-1 may, however, have cross-reactivity to other antigens, such as PD-1 molecules from other (non-human) species.
[0075] According to certain exemplary embodiments, an anti-PD-1 antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (HCVR), a light chain variable region (LCVR), and / or a complementarity determining region (CDR) comprising the amino acid sequence of any of the anti-PD-1 antibodies set forth in U.S. Patent No. 9,987,500, which is incorporated herein by reference in its entirety. In certain exemplary embodiments, an anti-PD-1 antibody, or antigen-binding fragment thereof, that can be used in the context of the present disclosure comprises a heavy chain complementarity determining region (HCDR) of the heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:11, and a light chain complementarity determining region (LCDR) of the light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:12. According to certain embodiments, the anti-PD-1 antibody, or antigen-binding fragment thereof, comprises three HCDRs (HCDR1, HCDR2, and HCDR3) and three LCDRs (LCDR1, LCDR2, and LCDR3), where HCDR1 comprises the amino acid sequence of SEQ ID NO: 13; HCDR2 comprises the amino acid sequence of SEQ ID NO: 14; HCDR3 comprises the amino acid sequence of SEQ ID NO: 15; LCDR1 comprises the amino acid sequence of SEQ ID NO: 16; LCDR2 comprises the amino acid sequence of SEQ ID NO: 17; and LCDR3 comprises the amino acid sequence of SEQ ID NO: 18. In yet other embodiments, the anti-PD-1 antibody, or antigen-binding fragment thereof, comprises a HCVR comprising SEQ ID NO: 11 and a LCVR comprising SEQ ID NO: 12. In certain embodiments, the methods of the disclosure comprise the use of an anti-PD-1 antibody, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO: 19. In some embodiments, the anti-PD-1 antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO: 20. An exemplary antibody comprising a HCVR comprising the amino acid sequence of SEQ ID NO:11 and a LCVR comprising the amino acid sequence of SEQ ID NO:12 is the fully human anti-PD-1 antibody known as cemiplimab (also known as REGN2810) (LIBTAYO®).
[0076] According to certain exemplary embodiments, the methods of the disclosure include the use of REGN2810, or a bioequivalent thereof. As used herein, the term "bioequivalent" with respect to an anti-PD-1 antibody refers to an anti-PD-1 antibody or PD-1 binding protein or fragment thereof that is a pharmaceutical equivalent or substitute having a rate and / or extent of absorption that does not significantly differ from that of a reference antibody (e.g., REGN2810) when administered in either single or multiple doses under similar experimental conditions at the same molar dose; the term "bioequivalent" also includes antigen binding proteins that bind to PD-1 and have no clinically meaningful differences from REGN2810 with respect to safety, purity and / or potency.
[0077] According to certain embodiments of the disclosure, the anti-human PD-1 antibody, or antigen-binding fragment thereof, comprises a HCVR having 90%, 95%, 98% or 99% sequence identity to SEQ ID NO:11.
[0078] According to certain embodiments of the disclosure, the anti-human PD-1 antibody, or antigen-binding fragment thereof, comprises an LCVR having 90%, 95%, 98% or 99% sequence identity to SEQ ID NO:12.
[0079] According to certain embodiments of the present disclosure, the anti-human PD-1 antibody, or antigen-binding fragment thereof, comprises a HCVR comprising the amino acid sequence of SEQ ID NO: 11, with no more than five amino acid substitutions. According to certain embodiments of the present disclosure, the anti-human PD-1 antibody, or antigen-binding fragment thereof, comprises a LCVR comprising the amino acid sequence of SEQ ID NO: 12, with no more than two amino acid substitutions.
[0080] Sequence identity can be measured by methods known in the art (eg, GAP, BESTFIT, and BLAST).
[0081] The disclosure also includes the use of anti-PD-1 antibodies in methods for treating cancer, wherein the anti-PD-1 antibodies comprise variants of any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein having one or more conservative amino acid substitutions. For example, the disclosure includes the use of anti-PD-1 antibodies having HCVR, LCVR and / or CDR amino acid sequences that have, e.g., 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc., conservative amino acid substitutions compared to any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein.
[0082] Other anti-PD-1 antibodies that can be used in the context of the present disclosure include, for example, nivolumab, pembrolizumab, MEDI0608, pidilizumab, BI 754091, spartalizumab (also known as PDR001), camrelizumab (also known as SHR-1210), sintilimab, AGEN2034, JNJ-63723283, MCLA-134, or any of the anti-PD-1 antibodies set forth in U.S. Patent Nos. 6,808,710, 7,488,802, 8,008,449, 8,168,757, 8,354,509, 8,609,089, 8,686,119, 8,779,105, 8,900,587, and 9,987,500, and in published patent applications WO2006 / 121168, WO2009 / 114335. The portions of the publications cited herein that identify anti-PD-1 antibodies are hereby incorporated by reference.
[0083] Anti-PD-1 antibodies used in the context of the methods of the present disclosure may have pH-dependent binding characteristics. For example, an anti-PD-1 antibody for use in the methods of the present disclosure may exhibit decreased binding to PD-1 at acidic pH compared to neutral pH. Alternatively, an anti-PD-1 antibody of the present disclosure may exhibit enhanced binding to its antigen at acidic pH compared to neutral pH. The phrase "acidic pH" includes pH values less than about 6.2, e.g., about 6.0, 5.95, 5.9, 5.85, 5.8, 5.75, 5.7, 5.65, 5.6, 5.55, 5.5, 5.45, 5.4, 5.35, 5.3, 5.25, 5.2, 5.15, 5.1, 5.05, 5.0, or lower. As used herein, the phrase "neutral pH" refers to a pH of about 7.0 to about 7.4. The expression "neutral pH" includes pH values of about 7.0, 7.05, 7.1, 7.15, 7.2, 7.25, 7.3, 7.35, and 7.4.
[0084] In certain instances, "decreased binding to PD-1 at acidic pH compared to neutral pH" refers to the K D Value vs. K for antibody binding to PD-1 at neutral pH D For example, an antibody or antigen-binding fragment thereof may be expressed in terms of a ratio of values (or vice versa) such that the antibody or antigen-binding fragment thereof has an acidic / neutral K of about 3.0 or greater. D When a ratio is presented, it may be considered for purposes of this disclosure to indicate "decreased binding to PD-1 at acidic pH compared to neutral pH." In the present disclosure, the acidic / neutral K D The ratio can be about 3.0, 3.5, 4.0, 4.5, 5.0, 5.5, 6.0, 6.5, 7.0, 7.5, 8.0, 8.5, 9.0, 9.5, 10.0, 10.5, 11.0, 11.5, 12.0, 12.5, 13.0, 13.5, 14.0, 14.5, 15.0, 20.0, 25.0, 30.0, 40.0, 50.0, 60.0, 70.0, 100.0 or more.
[0085] Antibodies with pH-dependent binding characteristics can be obtained, for example, by screening a population of antibodies for decreased (or enhanced) binding to a particular antigen at acidic pH compared to neutral pH. Furthermore, antibodies with pH-dependent characteristics can be obtained by modifying the antigen-binding domain at the amino acid level. For example, by replacing one or more amino acids in the antigen-binding domain (e.g., within the CDRs) with histidine residues, an antibody with decreased antigen binding at acidic pH compared to neutral pH can be obtained. As used herein, the phrase "acidic pH" refers to a pH of 6.0 or lower.
[0086] Anti-PD-L1 antibodies and their antigen-binding fragments In some embodiments, the PD-1 inhibitor used in the methods disclosed herein is an antibody or antigen-binding fragment thereof that specifically binds to PD-L1. For example, an antibody that "specifically binds" to PD-L1 as used in the context of this disclosure has a binding activity of about 1x10 -8 M or lower K D (For example, a smaller K D "High affinity" anti-PD-L1 antibodies include antibodies that bind to PD-L1 or portions thereof with a higher affinity (high affinity indicates tighter binding). TM or at least 10 -8 M, preferably 10 -9 M, more preferably 10 -10 M, and even more preferably 10 -11 M, and even more preferably 10 -12 K of M D " refers to a mAb that has binding affinity for PD-L1, expressed as " ". An isolated antibody that specifically binds human PD-L1 may, however, have cross-reactivity to other antigens, such as PD-L1 molecules from other (non-human) species.
[0087] According to certain exemplary embodiments, the anti-PD-L1 antibody, or antigen-binding fragment thereof, comprises a heavy chain variable region (HCVR), a light chain variable region (LCVR), and / or a complementarity determining region (CDR) comprising the amino acid sequence of any of the anti-PD-L1 antibodies set forth in U.S. Patent No. 9,938,345, which is incorporated herein by reference in its entirety. In certain exemplary embodiments, an anti-PD-L1 antibody, or antigen-binding fragment thereof, that can be used in the context of the present disclosure comprises a heavy chain complementarity determining region (HCDR) of the heavy chain variable region (HCVR) and a light chain complementarity determining region (LCDR) of the light chain variable region (LCVR), where the HCVR and LCVR comprise the amino acid sequence of the anti-PD-L1 antibody designated H1H8314N in U.S. Patent No. 9,938,345. According to certain embodiments, the anti-PD-L1 antibody, or antigen-binding fragment thereof, comprises three HCDRs (HCDR1, HCDR2, and HCDR3) and three LCDRs (LCDR1, LCDR2, and LCDR3), where HCDR1, HCDR2, HCDR3, LCDR1, LCDR2, and LCDR3 comprise the amino acid sequence of the anti-PD-L1 antibody designated H1H8314N in U.S. Patent No. 9,938,345. In yet other embodiments, the anti-PD-L1 antibody, or antigen-binding fragment thereof, comprises HCVRs and LCVRs that comprise the amino acid sequence of the anti-PD-L1 antibody designated H1H8314N in U.S. Patent No. 9,938,345.
[0088] According to certain embodiments of the disclosure, the anti-human PD-L1, or antigen-binding fragment thereof, comprises an LCVR that has 90%, 95%, 98% or 99% sequence identity to the LCVR amino acid sequence of the anti-PD-L1 antibody designated H1H8314N in U.S. Patent No. 9,938,345.
[0089] According to certain embodiments of the present disclosure, the anti-human PD-L1, or antigen-binding fragment thereof, comprises a HCVR that includes the amino acid sequence of the anti-PD-L1 antibody designated H1H8314N in U.S. Patent No. 9,938,345, with no more than five amino acid substitutions. According to certain embodiments of the present disclosure, the anti-human PD-L1, or antigen-binding fragment thereof, comprises a LCVR that includes the amino acid sequence of the anti-PD-L1 antibody designated H1H8314N in U.S. Patent No. 9,938,345, with no more than two amino acid substitutions.
[0090] Sequence identity can be measured by methods known in the art (eg, GAP, BESTFIT, and BLAST).
[0091] The disclosure also includes the use of anti-PD-L1 antibodies in methods of treating cancer, where the anti-PD-L1 antibodies comprise variants of any of the HCVR, LCVR and / or CDR amino acid sequences disclosed herein having one or more conservative amino acid substitutions. For example, the disclosure includes the use of anti-PD-L1 antibodies having HCVR, LCVR and / or CDR amino acid sequences that have, for example, 10 or fewer, 8 or fewer, 6 or fewer, 4 or fewer, etc., conservative amino acid substitutions compared to the HCVR, LCVR and / or CDR amino acid sequences disclosed herein.
[0092] Other anti-PD-L1 antibodies that can be used in the context of the methods of the present disclosure include those known in the art, such as MDX-1105, atezolizumab (TECENTRIQ), TM ), durvalumab (IMFINZI TM ), avelumab (BAVENCIO TM), LY3300054, FAZ053, STI-1014, CX-072, KN035 (Zhang et al., Cell Discovery, 3, 170004 (March 2017)), CK-301 (Gorelik et al., American Association for Cancer Research Annual Meeting (AACR), 2016-04-04 Abstract 4606), or antibodies described in patent publications US7943743, US8217149, US9402899, US9624298, US 9938345, WO 2007 / 005874, WO 2010 / 077634, WO 2013 / 181452, WO 2013 / 181634, WO 2016 / 149201, WO 2017 / 034916, or any of the other anti-PD-L1 antibodies set forth in EP 3177649. The portions of the publications cited herein that identify anti-PD-L1 antibodies are hereby incorporated by reference.
[0093] Pharmaceutical Compositions and Administration The disclosed methods include administering an IL-4 / IL-13 pathway inhibitor in combination with a PD-1 inhibitor to a subject in need thereof, where the inhibitors are contained in separate pharmaceutical compositions or in a combined (single) pharmaceutical composition. The pharmaceutical compositions of the present disclosure may be formulated with pharma- ceutical acceptable carriers, excipients, and other agents that provide for proper incorporation, delivery, tolerance, and the like. A large number of suitable formulations can be found in formularies known to all pharmaceutical chemists: Remington's Pharmaceutical Sciences, Mack Publishing Company, Easton, Pa. These formulations include, for example, powders, pastes, ointments, jellies, waxes, oils, lipids, lipid (cationic or anionic)-containing vesicles (e.g., LIPOFECTIN, 1997), and the like. TM), DNA conjugates, anhydrous absorbent pastes, oil-in-water and oil-in-water emulsions, emulsions carbowax (polyethylene glycol of various molecular weights), semi-solid gels, and semi-solid mixtures containing carbowax. See also Powell et al., 1998, J Pharm Sci Technol, 52:238-311.
[0094] In certain embodiments, the disclosed pharmaceutical compositions comprise a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4R antibody) and / or a therapeutically effective amount of a PD-1 inhibitor (e.g., an anti-PD-1 antibody) and a pharma- ceutical acceptable carrier. In certain embodiments, the disclosed pharmaceutical compositions are formulated for administration by injection, such as intravenous injection.
[0095] Various delivery systems are known and can be used to administer the pharmaceutical compositions of the present disclosure, for example, encapsulation in liposomes, microparticles, microcapsules, recombinant cells capable of expressing mutant viruses, receptor-mediated endocytosis (see, for example, Wu et al., 1987, J.Biol.Chem.262:4429-4432). Methods of administration include, but are not limited to, intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal, epidural, and oral routes. The compositions can be administered by any convenient route, for example, by infusion or bolus injection, by absorption through epithelial or mucocutaneous linings (e.g., oral mucosa, rectal and rectal mucosa, etc.), and may be administered together with other biologically active agents.
[0096] The pharmaceutical composition of the present disclosure can be delivered subcutaneously or intravenously using a standard needle and syringe. Furthermore, for subcutaneous delivery, a pen delivery device has ready utility in delivering the pharmaceutical composition of the present disclosure. Such a pen delivery device may be reusable or disposable. A reusable pen device generally utilizes a replaceable cartridge containing the pharmaceutical composition. Once all of the pharmaceutical composition in the cartridge has been administered and the cartridge is empty, the empty cartridge can be easily discarded and replaced with a new cartridge containing the pharmaceutical composition. The pen delivery device can then be reused. In a disposable pen delivery device, there is no replaceable cartridge. Rather, the disposable pen delivery device is sold pre-filled with the pharmaceutical composition held in a reservoir within the device. Once the pharmaceutical composition in the reservoir is emptied, the entire device is discarded.
[0097] In certain circumstances, one or both pharmaceutical compositions may be delivered in a controlled release system. In one embodiment, a pump may be used. In another embodiment, a polymeric material may be used. See Medical Applications of Controlled Release, Langer and Wise (eds.), 1974, CRC Pres., Boca Raton, Fla. In yet another embodiment, the controlled release system can be placed near the target of the composition, thus requiring only a fraction of the systemic dose (see, e.g., Goodson, 1984, MEDICAL APPLICATIONS OF CONTROLLED RELEASE, vol. 2, pp. 115-138). Other controlled release systems are discussed in Langer, 1990, Science 249:1527-1533.
[0098] Suitable injectable preparations may include dosage forms for intravenous, subcutaneous, intradermal, and intramuscular injections, drip infusions, and the like. These injectable preparations may be manufactured by known methods. For example, injectable preparations may be manufactured by dissolving, suspending, or emulsifying the above-mentioned antibody or a salt thereof in a sterile aqueous or oily medium conventionally used for injections. Aqueous media for injection include, for example, isotonic solutions containing physiological saline, glucose, and other auxiliary agents, and the like, which may be used in combination with a suitable solubilizing agent such as alcohol (e.g., ethanol), polyhydric alcohols (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], and the like. As oily media, for example, sesame oil, soybean oil, and the like are used, which may be dissolved in a suitable solvent such as benzyl benzoate, benzyl alcohol, and the like. The injection preparation thus prepared is preferably filled into a suitable ampoule.
[0099] Advantageously, the pharmaceutical compositions for oral or parenteral use are prepared in dosage forms with unit doses adapted to suit the dose of the active ingredient, such as tablets, pills, capsules, injections (ampoules), suppositories, etc.
[0100] Injectable formulations of pharmaceutical compositions can be prepared by known methods. For example, injectable formulations can be prepared by dissolving, suspending or emulsifying the inhibitor (e.g., anti-PD-1 antibody or anti-IL-4R antibody) or its salt in a sterile aqueous or oily medium conventionally used for injection. Aqueous media for injection include, for example, isotonic solutions containing physiological saline, glucose and other auxiliary agents, etc., which can be used in combination with suitable solubilizers such as alcohol (e.g., ethanol), polyhydric alcohols (e.g., propylene glycol, polyethylene glycol), nonionic surfactants [e.g., polysorbate 80, HCO-50 (polyoxyethylene (50 mol) adduct of hydrogenated castor oil)], etc. As oily media, for example, sesame oil, soybean oil, etc. can be used in combination with solubilizers such as benzyl benzoate, benzyl alcohol, etc. The injectable formulations thus prepared are preferably filled into suitable injection ampoules. In some embodiments, the injectable formulation may comprise a concentration of an inhibitor (e.g., an anti-PD-1 antibody or an anti-IL-4R antibody) and one or more pharma- ceutically acceptable solvents (e.g., distilled water, saline, etc.).
[0101] Exemplary pharmaceutical compositions comprising anti-IL-4R antibodies that can be used in the context of the present disclosure are disclosed, for example, in U.S. Patent No. 8,945,559, the portions of which identifying pharmaceutical compositions comprising anti-IL-4R antibodies are incorporated herein by reference. Pharmaceutical compositions comprising anti-PD-1 antibodies that can be used in the context of the present disclosure are disclosed, for example, in US 2019 / 0040137, the portions of which identifying pharmaceutical compositions comprising anti-PD-1 antibodies are incorporated herein by reference.
[0102] Drug Delivery Systems In some embodiments, a pharmaceutical composition for use in the disclosed methods may be provided in a pharmaceutical delivery system comprising: (i) a pharmaceutical composition comprising a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor; and (ii) a pharmaceutical composition comprising a therapeutically effective amount of a PD-1 inhibitor. In this aspect of the disclosure, these pharmaceutical compositions are separate from one another but may be provided in a single pharmaceutical delivery system or may be provided as a kit - i.e., a pharmaceutical delivery system accompanied by written instructions for use of the IL-4 / IL-13 pathway inhibitor in combination with a PD-1 inhibitor to treat or inhibit tumor growth as disclosed herein. In certain embodiments, the pharmaceutical delivery system comprises one or more doses of an IL-4 / IL-13 pathway inhibitor. In certain embodiments, the pharmaceutical delivery system comprises one or more doses of a PD-1 inhibitor.
[0103] In some embodiments, the pharmaceutical delivery system further comprises one or more additional therapeutic agents, such as any of the additional therapeutic agents described above. For example, the pharmaceutical delivery system comprising a pharmaceutical composition comprising an IL-4 / IL-13 pathway inhibitor and a pharmaceutical composition comprising a PD-1 inhibitor can be administered with or without cyclophosphamide, a cancer vaccine, a LAG3 inhibitor (e.g., an anti-LAG3 antibody), a CTLA-4 inhibitor (e.g., ipilimumab), a GITR agonist (e.g., an anti-GITR antibody), a TIM3 inhibitor, a CD28 activator, a BTLA inhibitor, a TIGIT inhibitor, a CD38 inhibitor, a CD47 inhibitor, an IDO inhibitor, a VEGF antagonist (e.g., a "VEGF trap" such as aflibercept or a VEGF inhibitor as described in US 7,087,411 ), or a combination of these. or other VEGF inhibitory fusion proteins such as those described above, or anti-VEGF antibodies or antigen-binding fragments thereof (e.g., bevacizumab, or ranibizumab) or small molecule kinase inhibitors of VEGF receptors (e.g., sunitinib, sorafenib, or pazopanib), Ang2 inhibitors (e.g., nesvacumab), TGFβ inhibitors, EGFR inhibitors (e.g., erlotinib, cetuximab), agonists for costimulatory receptors (e.g., agonists for CD28), VISTA inhibitors, CD40 agonists, CSF1R inhibitors, CCR2 inhibitors, CXCR4 inhibitors, CXCR2 In one embodiment, the therapeutic agent may further comprise one or more additional therapeutic agents selected from a medicament for treating a tumor, such as a medicament for treating a tumor, ... In one embodiment, the pharmaceutical delivery system is used in conjunction with surgery in a subject in need thereof.
[0104] Dosing regimen In some embodiments, the disclosed methods include sequentially administering to a subject in need thereof a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor in combination with a therapeutically effective amount of a PD-1 inhibitor, where each inhibitor is administered to the subject in one or more doses, e.g., as part of a particular therapeutic dosing regimen. In certain embodiments, the disclosed methods include administering the inhibitors for additive or synergistic activity to treat cancer, preferably a type 2 immune-dependent cancer, such as pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, brain cancer, skin cancer, prostate cancer, renal cancer, lung cancer, Hodgkin's lymphoma, or bladder cancer.
[0105] As used herein, "sequentially administering" means that each dose of the inhibitor is administered to the subject at different times, for example, on different days separated by a predetermined interval (e.g., hours, days, weeks, or months). In some embodiments, the disclosed methods include sequentially administering to the subject a single initial dose of an IL-4 / IL-13 pathway inhibitor, followed by one or more secondary doses of an IL-4 / IL-13 pathway inhibitor, and optionally followed by one or more tertiary doses of an IL-4 / IL-13 pathway inhibitor. In certain embodiments, the methods further include sequentially administering to the subject a single initial dose of a PD-1 inhibitor, followed by one or more secondary doses of a PD-1 inhibitor, and optionally followed by one or more tertiary doses of a PD-1 inhibitor.
[0106] In some embodiments, a therapeutic dosing regimen comprises administering one or more doses of an IL-4 / IL-13 pathway inhibitor in combination with one or more doses of a PD-1 inhibitor. In certain embodiments, the one or more doses of an IL-4 / IL-13 pathway inhibitor and / or the one or more doses of a PD-1 inhibitor are administered to a subject about once a day, once every two days, once every three days, once every four days, once every five days, once every six days, once a week, once every two weeks, once every three weeks, once every four weeks, once a month, once every two months, once every three months, once every four months, or less frequently.
[0107] As used herein, the phrase "in combination with" means that the IL-4 / IL-13 pathway inhibitor is administered before, after, or simultaneously with the PD-1 inhibitor. The term "in combination with" also refers to the sequential or simultaneous administration of an IL-4 / IL-13 pathway inhibitor and a PD-1 inhibitor. This also includes administration.
[0108] For example, when an IL-4 / IL-13 pathway inhibitor is administered "before" a PD-1 inhibitor, the IL-4 / IL-13 pathway inhibitor can be administered more than 150 hours, about 150 hours, about 100 hours, about 72 hours, about 60 hours, about 48 hours, about 36 hours, about 24 hours, about 12 hours, about 10 hours, about 8 hours, about 6 hours, about 4 hours, about 2 hours, about 1 hour, about 30 minutes, or about 15 minutes before administration of the PD-1 inhibitor. When an IL-4 / IL-13 pathway inhibitor is administered "after" a PD-1 inhibitor, the IL-4 / IL-13 pathway inhibitor can be administered about 15 minutes, about 30 minutes, about 1 hour, about 2 hours, about 4 hours, about 6 hours, about 8 hours, about 10 hours, about 12 hours, about 24 hours, about 36 hours, about 48 hours, about 60 hours, about 72 hours, or more than 72 hours after administration of the PD-1 inhibitor. Administration of an IL-4 / IL-13 pathway inhibitor "concurrently" with a PD-1 inhibitor means that the IL-4 / IL-13 pathway inhibitor is administered to the subject within 15 minutes (before, after, or simultaneously) of administration of the PD-1 inhibitor, either in a separate dosage form or as a single combined dosage formulation including both the IL-4 / IL-13 pathway inhibitor and the PD-1 inhibitor.
[0109] In certain embodiments, the disclosed methods include administration of an additional (eg, a third) therapeutic agent or treatment, such as any one of the agents or treatments enumerated herein.
[0110] As used herein, the terms "initial", "secondary", "tertiary", etc. refer to a time sequence of administration. Thus, an "initial dose" is a dose administered at the beginning of a treatment regimen (also referred to as a "baseline dose"); a "secondary dose" is a dose administered after the initial dose; and a "tertiary dose" is a dose administered after the secondary dose. The initial, secondary, and tertiary doses may all contain the same amount of IL-4 / IL-13 pathway inhibitor or PD-1 inhibitor. However, in certain embodiments, the amounts contained in the initial, secondary, and / or tertiary doses differ from each other during the course of treatment (e.g., adjusted upward or downward as needed). In certain embodiments, one or more (e.g., 1, 2, 3, 4, or 5) doses are administered as a "loading dose" at the beginning of a treatment regimen, followed by subsequent doses administered less frequently (e.g., "maintenance doses"). For example, an IL-4 / IL-13 pathway inhibitor or a PD-1 inhibitor may be administered to a patient with cancer at a loading dose of about 1 mg / kg to about 20 mg / kg of the patient's body weight, followed by one or more maintenance doses of about 0.1 mg / kg to about 10 mg / kg.
[0111] In one exemplary embodiment of the present disclosure, each secondary and / or tertiary dose is administered at a dose equal to or greater than the dose of the immediately preceding dose. 1 / 2 to 14 weeks or more (e.g., 1 / 2, 1, 1 1 / 2, 2, 2 1 / 2, 3, 3 1 / 2, 4, 5, 5 1 / 2, 6, 6 1 / 2, 7, 7 1 / 2, 8, 8 1 / 2, 9, 9 1 / 2, 10, 10 1 / 2 weeks or more after the first dose of an anti-PD-1 antibody. As used herein, the phrase "immediately prior to dosing" means that in a series of multiple doses, a dose of an anti-PD-1 antibody is administered to a subject without an intervening dose prior to administration of the next dose.
[0112] Similarly, an "initial treatment cycle" is a treatment cycle administered at the beginning of a treatment regimen; a "secondary treatment cycle" is a treatment cycle administered after the initial treatment cycle; and a "tertiary treatment cycle" is a treatment cycle administered after the secondary treatment cycle. In the context of this disclosure, the treatment cycles may be the same or different from one another.
[0113] Dosage In certain embodiments, at least one dose of an IL-4 / IL-13 pathway inhibitor comprises about 0.1-50 mg / kg, e.g., about 0.1-10 mg / kg, of the subject's body weight. For example, at least one dose may comprise about 0.1, 1, 0.3, 3, 4, 5, 6, 7, 8, 9, or 10 mg / kg of the subject's body weight. At least one dose of the IL-4 / IL-13 pathway inhibitor comprises about 0.05 to 1000 mg of an IL-4 / IL-13 pathway inhibitor, such as about 5, 10, 15, 20, 25, 40, 45, 50, 60, 70, 80, 90, 100, 200, 300, 400, 500, 600, 700, 800, 900 mg or more of an IL-4 / IL-13 pathway inhibitor. In one embodiment, the IL-4 / IL-13 pathway inhibitor is REGN668 (dupilumab).
[0114] In certain embodiments, at least one dose of the PD-1 inhibitor comprises about 0.1-20 mg / kg of the subject's body weight, e.g., about 0.1, 1, 0.3, 3, 4, 5, 6, 7, 8, 9, or 10 mg / kg of the subject's body weight. In certain embodiments, at least one dose of the PD-1 inhibitor comprises about 0.05-500 mg of the PD-1 inhibitor, e.g., about 5, 10, 15, 20, 25, 40, 45, 50, 60, 70, 80, 90, 100 mg or more of the PD-1 inhibitor. In one embodiment, the PD-1 inhibitor is REGN2810 (cemiplimab).
[0115] The amount of IL-4 / IL-13 pathway inhibitor and PD-1 inhibitor administered to a subject according to the methods disclosed herein is a therapeutically effective amount. As used herein, the term "therapeutically effective amount" refers to an amount of each inhibitor that results in one or more of the following: (a) a decrease in the severity or duration of symptoms or signs of cancer - e.g., tumor lesions; (b) inhibition of tumor growth or an increase in tumor necrosis, tumor shrinkage, and / or tumor disappearance; (c) a delay in tumor growth and development; (d) inhibition of tumor metastasis; (e) prevention of recurrence of tumor growth; (f) an increase in survival of subjects with cancer; and / or (g) a reduction in the use or need for conventional anti-cancer treatments (e.g., elimination of the need for surgery, or a reduction or elimination of the use of chemotherapy or cytotoxic drugs) compared to untreated subjects or subjects treated with either inhibitor as monotherapy.
[0116] In the case of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4R antibody), a therapeutically effective amount can be from about 0.05 mg to about 1000 mg of an IL-4 / IL-13 pathway inhibitor, e.g., about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 10 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150mg, about 160mg, about 170mg, about 180mg, about 190mg, about 200mg, about 210mg, about 220mg, about 230mg, about 240mg, about 250mg, about 260mg, about 270mg, about 280mg, about 290 mg, about 300mg, about 310mg, about 320mg, about 330mg, about 340mg, about 350mg, about 360mg, about 370mg, about 380mg, about 390mg, about 400mg, about 410mg, about 420mg, about 430mg, about 440mg, about 450mg, about 460mg, about 470mg, about 480mg, about 490mg, about 500mg, about 510mg, about 520mg, about 530mg, about 540mg, about 550mg, about 560mg, about 570mg, about 580 mg, about 590mg, about 600mg, about 610mg, about 620mg, about 630mg, about 640mg, about 650mg, about 660mg, about 670mg, about 680mg, about 690mg, about 700mg, about 710mg, about 720mg, about The amount of the IL-4 / IL-13 pathway inhibitor may be 730 mg, about 740 mg, about 750 mg, about 760 mg, about 770 mg, about 780 mg, about 790 mg, about 800 mg, about 810 mg, about 820 mg, about 830 mg, about 840 mg, about 850 mg, about 860 mg, about 870 mg, about 880 mg, about 890 mg, about 900 mg, about 910 mg, about 920 mg, about 930 mg, about 940 mg, about 950 mg, about 960 mg, about 970 mg, about 980 mg, about 990 mg, or about 1000 mg. In certain embodiments, 10 mg, 25 mg, 50 mg, 75 mg, 150 mg, 300 mg, 600 mg, or 900 mg of the IL-4 / IL-13 pathway inhibitor is administered to the subject.
[0117] In the case of a PD-1 inhibitor (e.g., an anti-PD-1 antibody), a therapeutically effective amount is about 0.05 For example, in various embodiments, the amount of PD-1 inhibitor can be about 0.05 mg, about 0.1 mg, about 1.0 mg, about 1.5 mg, about 2.0 mg, about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 250 mg, about 300 mg, about 350 mg, about 400 mg, about 450 mg, about 50 mg, about 60 mg, about 70 mg, about 80 mg, about 90 mg, about 100 mg, about 110 mg, about 120 mg, about 130 mg, about 140 mg, about 150 mg, about 160 mg, about 170 mg, about 180 mg, about 190 mg, about 200 mg, about 300 mg, about 40 ... The amount may be about 10 mg, about 220 mg, about 230 mg, about 240 mg, about 250 mg, about 260 mg, about 270 mg, about 280 mg, about 290 mg, about 300 mg, about 310 mg, about 320 mg, about 330 mg, about 340 mg, about 350 mg, about 360 mg, about 370 mg, about 380 mg, about 390 mg, about 400 mg, about 410 mg, about 420 mg, about 430 mg, about 440 mg, about 450 mg, about 460 mg, about 470 mg, about 480 mg, about 490 mg, or about 500 mg.
[0118] In certain embodiments, the amount of an individual dose of an IL-4 / IL-13 pathway inhibitor (e.g., an anti-IL-4R antibody) and / or a PD-1 inhibitor (e.g., an anti-PD-1 antibody) administered to a subject may be less than the therapeutically effective amount, i.e., sub-therapeutic. For example, if a therapeutically effective amount of an inhibitor comprises 3 mg / kg, a sub-therapeutic dose comprises an amount less than 3 mg / kg, e.g., 2 mg / kg, 1.5 mg / kg, 1 mg / kg, 0.5 mg / kg, or 0.3 mg / kg. As defined herein, a "sub-therapeutic dose" refers to an amount of an inhibitor that does not provide a therapeutic effect by itself. However, in certain embodiments, multiple sub-therapeutic doses of an inhibitor may be administered to collectively achieve a therapeutic effect in a subject. EXAMPLES
[0119] The disclosed technology will now be illustrated using the following examples. The use of these and other examples within this specification is for illustrative purposes only and does not limit the scope and meaning of the invention or any exemplified form in any way. Likewise, the invention is not limited to any particular preferred embodiment described herein. Indeed, modifications and variations of the invention may become apparent to those skilled in the art upon reading this specification, and modifications and variations can be made without departing from its spirit and scope. Thus, the present invention should be limited only by the terms of the claims, along with the full scope of equivalents to which the claims are entitled. Also, efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperature, etc.), but some experimental error and deviation should be accounted for. Unless otherwise indicated, parts are parts by weight, molecular weight is average molecular weight, temperature is in degrees Celsius, and pressure is at or near atmospheric pressure.
[0120] Example 1: Enhanced in vivo efficacy of IL-4R antibody in combination with anti-PD-1 antibody in a pancreatic cancer model This example relates to a study demonstrating the enhanced antitumor efficacy of IL-4R blockade in vivo as monotherapy alone and in combination with anti-PD-1 treatment using a KP organoid cell subcutaneous implantation model - i.e., a mouse model of human pancreatic cancer, type 2 immune-dependent cancer. In this study, 8-10 mice per treatment group were implanted with KP tumor organoid cells, and treatment of tumor-bearing mice was initiated at baseline with starting tumor volumes of 30-110 mm. 3 It started when the range was
[0121] The IL-4 / IL-13 pathway inhibitor used in this example is a murine anti-IL-4R antibody identified as REGN1103, which is a murine surrogate antibody of the human monoclonal antibody recognized as REGN668 (also known as dupilumab) specific for human IL-4R. REGN1103 is a HCVR / IL-13 antibody of SEQ ID NO: 21 / 22. REGN1103 contains the LCVR amino acid sequence pair and has affinity for mouse IL-4R in a range similar to that of dupilumab for human IL-4R. Furthermore, REGN1103 inhibits IL-4 and IL-13-dependent proliferation of cell lines with IC50s of 1.9 nM and 11 pM, respectively.
[0122] The PD-1 inhibitor used in this example was an anti-mouse PD-1 clone identified as RPMI-14 (Bio X Cell), which is a surrogate anti-PD-1 antibody commonly used in mouse syngeneic tumor models.
[0123] research design To assess whether type 2 immune responses were activated in an in vivo model of pancreatic cancer, IL-4 and IL-13 expression levels and IL-4 cytokine production were assessed in a transplant-based model of pancreatic cancer. Balb / c mice were subcutaneously or orthotopically implanted with syngeneic tumor organoid cells engineered to express oncogenic KRAS with simultaneous P53 tumor suppressor loss of function (KP), and tumors were harvested 4 weeks after implantation.
[0124] The KP organoid cell subcutaneous implantation model was also used to evaluate the antitumor efficacy of IL-4R blockade in vivo as monotherapy and / or in combination with anti-PD-1 ICB treatment.
[0125] Materials and Methods Animals. Balb / c mice were purchased from Jackson Laboratories and experiments were performed in accordance with IACUC approved guidelines.
[0126] KP organoid generation. Normal pancreatic epithelial organoids were isolated from pancreatic tissue of wild-type Balb / c mice. Pancreatic tissue was ground and digested in collagenase P buffer (Fisher Sci, 50-100-3398) for 15 min at 37°C. The cell suspension was passed through a 500 μm filter and then again through a 100 μm filter. The cells were then seeded on a matrigel overlay (VWR, 354234) using complete organoid medium; 1x P / S / L-glutamine, 1x B27 (Invitrogen), 1 mM N-acetylcysteine (Sigma-Aldrich), 10 nM h-gastrin (Sigma-Aldrich), 50 ng / ml mEGF (Life Technologies), 1 μg / ml mRSPO1 (Peprotech), 25 ng / ml DME / F12 supplemented with hNoggin (PeproTech), 100ng / ml hFGF10 (PeproTech), and 10mM nicotinamide (Sigma-Aldrich) (Boj et al., Mol Cell Oncol, 3(1):e1014757, 2015).
[0127] The resulting organoids were then maintained in growth factor-reduced Matrigel topped with complete organoid medium supplemented with 10 nM Rock inhibitor Y-27632 (Sigma-Aldrich, Y0503). To passage, organoids were washed out of the Matrigel using cell recovery solution (Corning) for 2 h on ice and then dissociated into a cell suspension using Accutase. Passage was performed once a week at a 1:4 ratio.
[0128] For lentiviral transduction of organoids, pancreatic organoids were dissociated into single-cell suspensions and transduced with KRas V12 For expression and loss of p53 expression, or p53 was detected using spinfection in the presence of polybrene (8 μg / ml). R175H The vector was transduced with lentivirus for expression of
[0129] The transduced KP-organoids were then cultured in the pancreatic head of syngeneic Balb / c mice. The mice were orthotopically implanted (0.1-0.5E6 cells in a 50:50 PBS / Matrigel solution per implant), which resulted in tumor growth within one month after implantation.
[0130] The resulting KP tumors were harvested and pancreatic cancer cells were isolated using collagenase XI / dispase solution overnight at 37° C. Cells were then washed with PBS and resuspended in growth factor-reduced Matrigel topped with complete organoid medium.
[0131] treatment In each treatment group (listed in Table 1 below), 8-10 mice were implanted with KP tumor organoid cells and tumors were allowed to establish (30-110 mm at baseline). 3 Treatment was initiated when tumor volume decreased (0.1E6–0.5E6 cells / mL). Mice were injected intraperitoneally with 25 mg / kg of REGN1103 (anti-mIL-4R antibody) or isotype control mIgG1 Ab in combination with 10 mg / kg of anti-mPD1 (clone RPMI-14) or isotype control rat IgG2a for 7 doses every 3–4 days starting 13 days after KP cell injection (0.1E6–0.5E6 cells).
[0132] [Table 1]
[0133] Balb / c mice were subcutaneously injected with 1E5–2.5E5 syngeneic KP organoid-derived cells in 50:50 PBS / Matrigel. Cells were tested prior to in vivo implantation using the IMPACT test. Tumors were measured twice weekly by caliper and volumes were calculated (L*W). 2 ) / 2, where L is the longest diameter and W is the perpendicular diameter.
[0134] result IL-4 and IL-13 gene expression was found to be significantly upregulated in orthotopic and subcutaneously implanted tumors compared to normal pancreas, which lacked expression of IL-4 and IL-13 genes. Similarly, IL-4 cytokine production, measured by ELISA assay, was significantly upregulated in both orthotopic and subcutaneous tumor models, whereas normal pancreas did not show IL-4 cytokine production. These data showed that KP organoid cell implanted tumor models of pancreatic cancer expressed high levels of IL-4 and IL-13, which are two central type 2-related cytokines, thereby indicating that type 2 immune responses are activated in these in vivo models of pancreatic cancer.
[0135] Furthermore, anti-IL-4R treatment enhanced the antitumor efficacy of PD-1 blockade in vivo. 3 The results of the treatment study on tumor volume are shown in Figures 1A and 1B. 3 The results of the subgroup of treated mice with tumors of tumor volume are shown in Figures 2A and 2B. Anti-mPD-1 monotherapy showed partial anti-tumor efficacy with 4 out of 8 mice showing tumor regression, including 2 complete responses, whereas anti-mIL-4R monotherapy showed no anti-tumor activity. However, anti-IL-4R and anti-PD-1 combination therapy showed dramatically enhanced anti-tumor efficacy with 7 out of 10 mice showing tumor regression, including 6 complete responses. This was an unexpectedly excellent result.
[0136] Thus, IL-4 / IL-13 type 2 immune responses in type 2 immune-dependent cancers can be effectively targeted by blocking the IL-4 / IL-13 pathway.This study shows that in a subcutaneous animal model of pancreatic cancer, a representative type 2 immune-dependent cancer, anti-IL-4R therapy substantially enhances the antitumor efficacy of anti-PD-1 treatment to a surprising extent.
[0137] Example 2: Subsets in human pancreatic cancer and other human cancer types display a strong type 2 immune signature To assess the extent of type 2 immune response activation within and across human cancer types, a type 2 immunity gene signature was designed that included type 2-associated cytokines, chemokines, and their receptors, as well as type 2 immunity downstream target genes (IL-13RA2, IL25, IL17RB, SERPINB2, CCL24, CEACAM1, CCL1, MUC5B, CCL26, IL-13RA1, POSTN, IL6R, CCL18, CCL17, FCER2, CCR3, IL6, CCL8, CRLF2, IL33, TSLP, IL-4R, CCR4, PTGDR, FCER1A, IL1RL1, DPP4, IL-4, IL5, and IL-13). This type 2 immune signature was applied to expression profiles of multiple human cancer types available from The Cancer Genome Atlas (TCGA) database - namely, BRCA (breast cancer), COAD (colon adenocarcinoma), GBM (glioblastoma multiforme), KIRC (renal cell carcinoma), LGG (low-grade glioma), LUAD (lung adenocarcinoma), LUSC (lung squamous cell carcinoma), OV (ovarian cancer), PAAD (pancreatic adenocarcinoma), PRAD (prostate adenocarcinoma), and SKCM (cutaneous melanoma). The top quartile normalized expression values at FPKM (fragments per kilobase of transcript per million mapped reads) were used as the original input. Z-scores were generated for each gene expression across all tumor samples shown in the heatmap. For the Th2 signature score calculation, the upper limit of Z-score (highest Z-score) was set to +4; and the lower limit of Z-score (lowest Z-score) was set to -4. The sum of the Z-scores for each gene in the Th2 signature gene list was then calculated for each sample, and the combined expression (Z-score) represents the Th2 signature level of the sample.
[0138] Analysis of this type 2 immune signature heat map showed that pancreatic cancer, non-small cell lung cancer, and lung squamous cell carcinoma showed the strongest overall expression of the type 2 immune signature with minimal heterogeneity. Subsets within other cancer types also showed a strong overall type 2 immune signature, including subsets in breast and colon cancer. However, other cancer types (e.g., glioblastoma multiforme (GBM), glioma, melanoma, prostate) showed low overall expression of the signature. In summary, these data show strong type 2 immune activity in human pancreatic and lung cancer, as well as in other human cancer types, including breast and colon cancer.
[0139] Example 3: IL-4 and IL-13 cytokines are significantly upregulated and produced in an in vivo model of pancreatic cancer This example demonstrates the efficacy and safety of IL-4 and IL-13 expression levels in an in vivo model of pancreatic cancer by assessing IL-4 and IL-13 expression levels and IL-4 cytokine production in a transplant-based model of pancreatic cancer. The materials and methods described in Example 1 for animal and KP organoid generation are the same for this Example 3.
[0140] Balb / c mice were implanted subcutaneously (Sub-Cu) or orthotopically (Ortho) with syngeneic pancreatic organoid cells (KP cells) engineered to express oncogenic KRAS with concomitant loss of function of the P53 tumor suppressor, and tumors were harvested 4 weeks after implantation (n=4–5 per condition).
[0141] Cytokine measurements. Tumor samples were resuspended in tissue protein extraction reagent (T-PER; Thermo Fisher, Waltham, Mass.) supplemented with a protease inhibitor cocktail and mechanically homogenized using a TissueLyser II (Qiagen, Hilden, Germany). Protein content in tumor protein extracts was determined by Bradford assay (Pierce TMCytokine concentrations were determined using a custom MSD kit and a QuickPlex SQ120 plate reader (Meso Scale Discovery, Rockville, MD).
[0142] result Both IL-4 and IL-13 gene expression was found to be significantly upregulated in orthotopically and subcutaneously implanted tumors compared to normal pancreas, which had no expression of IL-4 and IL-13 genes (Figure 3A). Similarly, IL-4 cytokine production, measured by ELISA assay, was upregulated in both orthotopic and subcutaneous tumor models, whereas normal pancreas showed no production of IL-4 cytokine (Figure 3B). These data showed that KP organoid cell implanted tumor models of pancreatic cancer express high levels of IL-4 and IL-13, two central type 2 immune-related cytokines, thereby indicating that type 2 immune responses are activated in these in vivo models of pancreatic cancer. Thus, IL-4 / IL-13-induced type 2 immune responses can be effectively targeted by IL-4R blockade (Harb et al., Clin Exp Allergy, 50(1):5-14, 2019; Le Floc'h et al., Allergy, Dec 2019).
[0143] Example 4: Combined anti-IL-4R and anti-PD-1 blockade consistently results in enhanced anti-tumor efficacy in larger tumors This example is a repeat study of Example 1 and evaluated the efficacy of combined anti-IL-4R / PD-combination therapy on larger tumors. Specifically, in this study, established tumors were 70-100 mm 3 It was started when the volume was in the range of
[0144] result Anti-IL4R monotherapy showed a trend towards tumor growth control, whereas anti-mPD-1 monotherapy showed no overall anti-tumor activity. In contrast, anti-IL-4R / PD-1 combination therapy showed significantly enhanced anti-tumor efficacy compared to the monotherapy control arm, controlling tumor growth in 4 of 7 mice. The results of this treatment study are shown in Figures 4A and 4B.
[0145] Additionally, systemic interferon gamma (IFNg) and tumor necrosis factor alpha (TNFa) cytokine levels were measured in tumor lysates at the end of the study. IFNg and TNFa production were significantly increased in the combination treatment groups compared to the single agent or isotype control groups (Figure 4C). Notably, the highest levels of intratumoral IFNg (>50 pg / mL) corresponded to the most responsive tumors in each treatment group. Overall, the aforementioned findings support the increased IFNg-dependent antitumor activity of anti-IL-4R / PD-1 combination treatment. This indicates that the above-mentioned
[0146] Example 5: Combined anti-IL-4R and anti-PD-1 blockade exhibits cancer stromal and immune modulating activity This example is a repeat study of Example 1, but examined the stromal and immune modulating activity of anti-IL-4R / PD-1 combination therapy in PDAC tumor-bearing mice. Histological analysis of stromal content was performed in this short end-point treatment study, in which 8-10 mice per treatment group were implanted with KP tumor organoid cells. 3 Treatment was initiated when tumor volume reached 100 mg / kg / day. Tumors were harvested after two treatment doses to avoid excessive tumor regression and allow for unbiased histological analysis. The percent change in treated volume for treatment groups is shown in Figure 5A.
[0147] Hyaluronic acid (HA) is a prominent component of the pancreatic tumor microenvironment and has been shown to inhibit drug perfusion within the tumor matrix (Provenzano et al., Cancer Cell, 21(3):418-29, 2012; Jacobetz et al., Gut, 62(1):112-20, 2013). Enzymatic depletion of HA has been shown to enhance cytotoxic antitumor efficacy in PDAC preclinical models and will be tested in pancreatic cancer patients in combination with chemotherapy or immune checkpoint blockade. HA content in the pancreatic tumor microenvironment was determined using histochemical staining methods to detect biotinylated HA binding protein (HABP) and digital pathology analysis (Figure 5B).
[0148] Immunostaining. Samples were fixed in 10% neutral formalin for 16-24 hours and transferred to 70% ethanol for paraffin embedding. All staining was performed on 5uM paraffin sections of mouse tissues.
[0149] For immunostaining, sections were deparaffinized, dehydrated, and antigen retrieval was performed at RT. Staining was performed with Citra solution (Biogenex, San Ramon, CA) and endogenous peroxidase was blocked using H2O2. Nonspecific protein binding was blocked with 10% goat serum (Sigma, St Louis, MA). Sections were incubated overnight at 4°C with anti-CD8 primary antibody (Cell Signaling Technologies, Danvers, MA) and horseradish peroxidase-conjugated secondary antibody (Cell Signaling Technologies). The remaining steps were performed with hematoxylin counterstaining using the appropriate Vectastain Elite ABC kit (Vector Labs.) and DAB peroxidase substrate (Vector Labs.). Digital quantification of HABP deposition and CD8 T cell density was performed using the HALO image analysis platform from Indica Labs.
[0150] HA histochemistry. Biotinylated HA binding protein (bHABP, Millipore Danvers MA USA was used. Sections were deparaffinized, rehydrated, and blocked with 3% bovine serum albumin (BSA) before being incubated with bHABP (1:200 in 1% BSA) overnight at 4°C. The remaining steps were performed using Vectastain Elite ABC kit Standard (Vector Labs. Burlingame CA) and DAB peroxidase substrate (Vector Labs.) with hematoxylin counterstain.
[0151] result Figure 5A shows the percent change in tumor volume (relative to baseline) at the end of the study. HA content was dramatically reduced in the anti-IL-4R monotherapy and anti-IL-4R / PD-1 combination treatment groups compared to the anti-PD-1 monotherapy and isotype control groups. (Fig. 5B). This decrease in HA content was clearly associated with increased CD8+ T cell infiltration within the tumor matrix in the anti-IL-4R / PD-1 combination treatment group, as shown by histological quantification of the tumor-infiltrating lymphocyte (TIL) marker CD8 (Fig. 5C). Moreover, increased T cell infiltration was associated with a pronounced synergistic antitumor efficacy in the anti-IL-4R / PD-1 combination treatment group.
[0152] The above data indicate that in the context of type 2 immune-polarized fibrotic pancreatic tumors, IL-4R blockade exerts antitumor activity through a dual mechanism of action: (i) potent stromal modulation and regulation of HA deposition; and (ii) significantly enhanced TIL infiltration when combined with anti-PD-1 treatment.
[0153] Example 6: Efficacy of anti-human PD-1 antibody in combination with anti-IL-4R antibody against transplanted tumors For the experiments in this example, humanized mice expressing the extracellular portion of human PD-1 and the transmembrane and intracellular portions of the mouse version of this protein were generated using VelociGene® technology (Valenzuela et al 2003, Nat. Biotechnol. 21:652-659; see also US 9,987,500).
[0154] The exemplary anti-PD-1 antibody used in this study is a fully human antibody (cemiplimab) that specifically binds to human PD-1 and comprises HCDR1-HCDR2-HCDR3-LCDR1-LCDR2-LCDR3 of SEQ ID NOs: 13-14-15-16-17-18 and HCVR / LCVR of SEQ ID NOs: 11 / 12. An exemplary IL-4 / IL-13 pathway inhibitor used in this example is described in Example 1.
[0155] Pancreatic epithelial organoids were isolated from PD-1 humanized mice and treated as described in Example 1 to obtain KP-tumor organoid cells (pancreatic cancer cells).
[0156] 1.5x10 in PD-1-humanized mice 6 KP-tumor organoid cells were implanted on day 0, and treatment began once tumors were established. Mice were injected intraperitoneally with REGN1103 (anti-mIL-4R antibody) 25 mg / kg or isotype control Ab in combination with cemiplimab 10 mg / kg or isotype control, for 7 doses (0.1E6-0.5E6 cells) every 3-4 days starting 13 days after KP cell injection. Tumor volumes were monitored twice weekly for the duration of the experiment by caliper measurement.
[0157] Anti-IL-4R treatment enhances the antitumor efficacy of cemiplimab: Tumor regression and complete responses were seen in mice treated with the combination therapy compared to cemiplimab monotherapy.
[0158] Example 7: Clinical Trials In clinical trials, patients with pancreatic, lung, multiple myeloma, breast and colon cancer were given cemiplimab in combination with dupilumab. Patients who received cemiplimab and dupilumab showed greater tumor inhibition than patients who received either drug as monotherapy.
Claims
1. 1. A method of treating a tumor or inhibiting tumor growth, comprising: (a) selecting a subject having a tumor; and (b) administering to a subject in need thereof a therapeutically effective amount of an IL-4 / IL-13 pathway inhibitor and a therapeutically effective amount of a programmed death 1 (PD-1) inhibitor.
2. 2. The method of claim 1, wherein the tumor comprises colorectal cancer, ovarian cancer, prostate cancer, bladder cancer, breast cancer, brain cancer, cervical cancer, bladder cancer, anal cancer, uterine cancer, colon cancer, liver cancer, pancreatic cancer, lung cancer, endometrial cancer, bone cancer, testicular cancer, skin cancer, kidney cancer, stomach cancer, esophageal cancer, head and neck cancer, salivary gland cancer, myeloma, Hodgkin's lymphoma, non-Hodgkin's lymphoma, follicular lymphoma, small lymphocytic lymphoma, lymphoplasmacytic lymphoma, marginal zone lymphoma, mantle cell lymphoma, diffuse large B-cell lymphoma, B-cell lymphoma, lymphomatoid granulomatosis, Burkitt's lymphoma, acute lymphocytic leukemia, hairy cell leukemia, or B-cell chronic lymphocytic leukemia.
3. The method of claim 1 or 2, wherein the tumor comprises a type 2 immune-dependent cancer.
4. 4. The method of claim 3, wherein the type 2 immune-dependent cancer comprises pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, brain cancer, skin cancer, prostate cancer, kidney cancer, lung cancer, Hodgkin's lymphoma, or bladder cancer.
5. The method of any one of claims 1 to 4, wherein the tumor comprises a pancreatic cancer.
6. The method of any one of claims 1 to 4, wherein the tumor comprises non-small cell lung cancer.
7. The method of any one of claims 1 to 4, wherein the tumor comprises lung squamous cell carcinoma.
8. The method of any one of claims 1 to 7, wherein the tumor is primary, metastatic, or recurrent.
9. The method of any one of claims 1 to 8, wherein the subject has been previously treated with an anti-tumor therapeutic agent or treatment.
10. The method of any one of claims 1 to 9, wherein the subject has been treated with a PD-1 inhibitor.
11. The method of any one of claims 1 to 10, wherein the tumor is resistant or unresponsive to prior treatment with a therapeutic agent or therapy.
12. The method of any one of claims 1 to 11, wherein the subject exhibits upregulation of at least one cytokine.
13. The method of claim 12, wherein the at least one cytokine comprises at least one of IL-4 and IL-13.
14. The method of any one of claims 1 to 13, wherein the subject exhibits increased production of at least one cytokine.
15. The method of claim 14, wherein the at least one cytokine comprises IL-4.
16. The method of any one of claims 1 to 15, wherein the subject exhibits increased hyaluronic acid (HA) content in tumors.
17. 17. The method of any one of claims 1 to 16, wherein the IL-4 / IL-13 pathway inhibitor is selected from the group consisting of an anti-IL-4 antibody, an anti-IL-13 antibody, an anti-IL-4 / IL-13 bispecific antibody, an IL-4 receptor (IL-4R) inhibitor, an IL-4 trap, an IL-13 trap, and an anti-IL-4R antibody.
18. The method of any one of claims 1 to 17, wherein the IL-4 / IL-13 pathway inhibitor is an anti-IL-4 antibody.
19. The method of any one of claims 1 to 17, wherein the IL-4 / IL-13 pathway inhibitor is an anti-IL-13 antibody.
20. The method of any one of claims 1 to 17, wherein the IL-4 / IL-13 pathway inhibitor is an anti-IL-4 / IL-13 bispecific antibody.
21. The method of any one of claims 1 to 17, wherein the IL-4 / IL-13 pathway inhibitor is an IL-4R inhibitor.
22. The method of any one of claims 1 to 17, wherein the IL-4 / IL-13 pathway inhibitor is an anti-IL-4R antibody.
23. The method of claim 17 or 22, wherein the anti-IL-4R antibody comprises a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:
2.
24. The method of claim 17 or 22, wherein the anti-IL-4R antibody comprises a HCVR comprising three heavy chain complementarity determining regions (CDRs) (HCDR1, HCDR2 and HCDR3) and a LCVR comprising three light chain CDRs (LCDR1, LCDR2 and LCDR3), where: HCDR1 has the amino acid sequence of SEQ ID NO:3; HCDR2 has the amino acid sequence of SEQ ID NO:4; HCDR3 has the amino acid sequence of SEQ ID NO:5; LCDR1 has the amino acid sequence of SEQ ID NO:6; LCDR2 has the amino acid sequence of SEQ ID NO:7; and LCDR3 has the amino acid sequence of SEQ ID NO:
8.
25. 25. The method of claim 24, wherein the HCVR comprises the amino acid sequence of SEQ ID NO:1 and the LCVR comprises the amino acid sequence of SEQ ID NO:
2.
26. The method of any one of claims 17 and 22-25, wherein the anti-IL-4R antibody comprises a heavy chain and a light chain, wherein the heavy chain has the amino acid sequence of SEQ ID NO:
9.
27. The method of any one of claims 17 and 22-25, wherein the anti-IL-4R antibody comprises a heavy chain and a light chain, wherein the light chain has the amino acid sequence of SEQ ID NO:
10.
28. The method of any one of claims 17 and 22-25, wherein the anti-IL-4R antibody comprises a heavy chain and a light chain, wherein the heavy chain has the amino acid sequence of SEQ ID NO:9 and the light chain has the amino acid sequence of SEQ ID NO:
10.
29. The method of any one of claims 1 to 17 and 22 to 28, wherein the IL-4 / IL-13 pathway inhibitor is dupilumab or a biological equivalent thereof.
30. 18. The method of any one of claims 1 to 17, wherein the IL-4 / IL-13 pathway inhibitor is selected from the group consisting of dupilumab, pascolizumab, AMG317, MEDI2045, MEDI9314, tralokinumab, lebricizumab, anrukinzumab, dextrekumab, GSK679586, MEDI7836, romilkimab, IL-4 trap, IL-13 trap, AER-003, and pitrakinra.
31. The method of any one of claims 1 to 30, wherein the PD-1 inhibitor is selected from an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody.
32. 32. The method of any one of claims 1 to 31, wherein the PD-1 inhibitor is an anti-PD-1 antibody comprising an HCVR comprising the amino acid sequence of SEQ ID NO:11 and an LCVR comprising the amino acid sequence of SEQ ID NO:
12.
33. The method of claim 32, wherein the HCVR comprises three heavy chain CDRs (HCDR1, HCDR2 and HCDR3) and the LCVR comprises three light chain CDRs (LCDR1, LCDR2 and LCDR3), where: HCDR1 has the amino acid sequence of SEQ ID NO: 13; HCDR2 has the amino acid sequence of SEQ ID NO: 14; HCDR3 has the amino acid sequence of SEQ ID NO: 15; LCDR1 has the amino acid sequence of SEQ ID NO: 16; LCDR2 has the amino acid sequence of SEQ ID NO: 17; and LCDR3 has the amino acid sequence of SEQ ID NO:
18.
34. The method of claim 32 or 33, wherein the anti-PD-1 antibody comprises the HCVR / LCVR sequence pair of SEQ ID NOs: 11 / 12.
35. The method of any one of claims 32 to 34, wherein the anti-PD-1 antibody comprises a heavy chain and a light chain, wherein the heavy chain has the amino acid sequence of SEQ ID NO:
19.
36. The method of any one of claims 32 to 34, wherein the anti-PD-1 antibody comprises a heavy chain and a light chain, wherein the light chain has the amino acid sequence of SEQ ID NO:
20.
37. 35. The method of any one of claims 32-34, wherein the anti-PD-1 antibody comprises a heavy chain and a light chain, wherein the heavy chain has the amino acid sequence of SEQ ID NO:19 and the light chain has the amino acid sequence of SEQ ID NO:
20.
38. The method of any one of claims 1 to 37, wherein the PD-1 inhibitor is cemiplimab or a biological equivalent thereof.
39. The method of any one of claims 1 to 31, wherein the PD-1 inhibitor is an anti-PD-1 antibody selected from the group consisting of cemiplimab, nivolumab, pembrolizumab, pidilizumab, MEDI0608, BI 754091, PF-06801591, sintilimab, AGEN2034, spartalizumab, camrelizumab, JNJ-63723283, and MCLA-134.
40. The method of any one of claims 1 to 31, wherein the PD-1 inhibitor is an anti-PD-L1 antibody selected from the group consisting of H1H8314N, avelumab, atezolizumab, durvalumab, MDX-1105, LY3300054, FAZ053, STI-1014, CX-072, KN035, and CK-301.
41. The method of any one of claims 1 to 40, wherein one or more doses of an IL-4 / IL-13 pathway inhibitor are administered in combination with one or more doses of an anti-PD-1 antibody. method.
42. 42. The method of claim 41, wherein at least one dose of the IL-4 / IL-13 pathway inhibitor comprises from about 0.1 to about 50 mg / kg of the subject's body weight.
43. 42. The method of claim 41, wherein at least one dose of the IL-4 / IL-13 pathway inhibitor comprises from about 0.05 to about 1000 mg of the inhibitor.
44. 44. The method of any one of claims 41-43, wherein each dose of the IL-4 / IL-13 pathway inhibitor is administered 0.5 to 12 weeks after the immediately preceding dose.
45. 45. The method of any one of claims 41-44, wherein at least one dose of the PD-1 inhibitor comprises from about 0.1 mg / kg to about 20 mg / kg of the subject's body weight.
46. 45. The method of any one of claims 41-44, wherein at least one dose of the PD-1 inhibitor comprises from about 0.05 to about 500 mg of the inhibitor.
47. 47. The method of claim 45 or 46, wherein each dose of the PD-1 inhibitor is administered 0.5 to 12 weeks after the immediately preceding dose.
48. 48. The method of any one of claims 1 to 47, wherein the IL-4 / IL-13 pathway inhibitor is administered simultaneously with the PD-1 inhibitor.
49. 48. The method of any one of claims 1 to 47, wherein the IL-4 / IL-13 pathway inhibitor is administered prior to the PD-1 inhibitor.
50. 48. The method of any one of claims 1 to 47, wherein the IL-4 / IL-13 pathway inhibitor is administered after the PD-1 inhibitor.
51. 51. The method of any one of claims 1 to 50, which promotes tumor regression, slows tumor growth, reduces tumor cell burden, reduces tumor burden, and / or prevents tumor recurrence in a patient.
52. 52. The method of any one of claims 1-51, which promotes tumor regression by at least about 10% more in treated subjects compared to untreated subjects or subjects treated with either inhibitor as monotherapy.
53. 52. The method of any one of claims 1 to 51, which results in at least a 30% or greater reduction in tumor cells or tumor size compared to untreated subjects or subjects treated with either inhibitor as monotherapy.
54. 54. The method of any one of claims 1 to 53, further comprising administering at least one further therapeutic agent or at least one further treatment.
55. The additional therapeutic agent or treatment may be chemotherapy, cyclophosphamide, surgery, radiation, a cancer vaccine, a LAG3 inhibitor, a CTLA-4 inhibitor, a GITR agonist, a TIM3 inhibitor, a BTLA inhibitor, a TIGIT inhibitor, a CD38 inhibitor, a CD47 inhibitor, an IDO inhibitor, a VEGF antagonist, an Ang2 inhibitor, a TGFβ inhibitor, an EGFR inhibitor, a VISTA inhibitor, a CD40 agonist, a CSF1R inhibitor, a CCR2 inhibitor, a CXCR4 inhibitor, a CXCL12 inhibitor, a CD28 activator, 55. The method of claim 54, comprising administering to a subject an agonist for a stimulatory receptor, an antibody for a tumor-specific antigen, an anti-CD3 / anti-CD20 bispecific antibody, GM-CSF, a cytotoxin, a chemotherapeutic agent, an oncolytic virus, an IL-6R inhibitor, an IL-10 inhibitor, a cytokine, an ADC, a chimeric antigen receptor T cell, an anti-inflammatory drug, an NSAID, and / or a nutritional supplement.
56. (a) a pharmaceutical composition comprising an IL-4 / IL-13 pathway inhibitor and a pharma- ceutical acceptable carrier; and (b) a pharmaceutical composition comprising a programmed death 1 (PD-1) inhibitor; and a pharma- ceutical delivery system comprising:
57. 57. The pharmaceutical delivery system of claim 56, wherein pharmaceutical compositions (a) and (b) are separate from each other.
58. 58. The pharmaceutical delivery system of claim 56 or 57, wherein the pharmaceutical composition (a) comprises one or more doses of an IL-4 / IL-13 pathway inhibitor.
59. 59. The pharmaceutical delivery system of claim 58, wherein at least one dose comprises about 5 to 1000 mg of the IL-4 / IL-13 pathway inhibitor.
60. 60. The pharmaceutical delivery system of any one of claims 56 to 59, wherein pharmaceutical composition (b) comprises one or more doses of a PD-1 inhibitor.
61. 61. The pharmaceutical delivery system of claim 60, wherein at least one dose comprises about 5 to 500 mg of the PD-1 inhibitor.
62. 62. The pharmaceutical delivery system of any one of claims 56 to 61, wherein the IL-4 / IL-13 pathway inhibitor is selected from the group consisting of an anti-IL-4 antibody, an anti-IL-13 antibody, an anti-IL-4 / IL-13 bispecific antibody, an IL-4 receptor (IL-4R) inhibitor, an IL-4 trap, an IL-13 trap, and an anti-IL-4R antibody.
63. 63. The pharmaceutical delivery system of claim 62, wherein the IL-4 / IL-13 pathway inhibitor is selected from the group consisting of dupilumab, pascolizumab, AMG317, MEDI2045, MEDI9314, tralokinumab, lebricizumab, anrukinzumab, dextrekumab, GSK679586, MEDI7836, romilkimab, IL-4 trap, IL-13 trap, AER-003, and pitrakinra.
64. The pharmaceutical delivery system of any one of claims 56 to 63, wherein the PD-1 inhibitor is selected from the group consisting of an anti-PD-1 antibody, an anti-PD-L1 antibody, and an anti-PD-L2 antibody.
65. The pharmaceutical delivery system of any one of claims 56 to 64, wherein the PD-1 inhibitor is an anti-PD-1 antibody selected from the group consisting of cemiplimab, nivolumab, pembrolizumab, pidilizumab, MEDI0608, BI 754091, PF-06801591, sintilimab, AGEN2034, spartalizumab, camrelizumab, JNJ-63723283, and MCLA-134.
66. The pharmaceutical delivery system of any one of claims 56 to 64, wherein the PD-1 inhibitor is an anti-PD-L1 antibody selected from the group consisting of H1H8314N, avelumab, atezolizumab, durvalumab, MDX-1105, LY3300054, FAZ053, STI-1014, CX-072, KN035, and CK-301.
67. Cyclophosphamide, cancer vaccine, LAG3 inhibitor, CTLA-4 inhibitor, GITR 67. The pharmaceutical delivery system of any one of claims 56 to 66, further comprising at least one additional therapeutic agent selected from the group consisting of: agonists, TIM3 inhibitors, BTLA inhibitors, TIGIT inhibitors, CD38 inhibitors, CD47 inhibitors, IDO inhibitors, VEGF antagonists, Ang2 inhibitors, TGFβ inhibitors, EGFR inhibitors, VISTA inhibitors, CD28 activators, CD40 agonists, CSF1R inhibitors, CCR2 inhibitors, CXCR4 inhibitors, CXCL12 inhibitors, agonists for costimulatory receptors, antibodies against tumor specific antigens, anti-CD3 / anti-CD20 bispecific antibodies, GM-CSF, cytotoxins, chemotherapeutic agents, IL-6R inhibitors, IL-10 inhibitors, oncolytic viruses, cytokines, ADCs, chimeric antigen receptor T cells, anti-inflammatory drugs, NSAIDs, and dietary supplements.
68. A pharmaceutical delivery system according to any one of claims 56 to 67 for use in treating or inhibiting the growth of a tumour.
69. The pharmaceutical delivery system of claim 68, wherein the tumor comprises a type 2 immune-dependent cancer.
70. 70. A kit comprising the pharmaceutical delivery system of any one of claims 56-69 and written instructions for use of an IL-4 / IL-13 pathway inhibitor in combination with a PD-1 inhibitor to treat or inhibit the growth of a tumor.
71. 1. An IL-4 / IL-13 pathway inhibitor for use in a method of treating or inhibiting the growth of a tumor in combination with a programmed death 1 (PD-1) inhibitor, the method comprising administering to a subject in need thereof a therapeutically effective amount of each inhibitor.
72. 1. A programmed death 1 (PD-1) inhibitor in combination with an IL-4 / IL-13 pathway inhibitor for use in a method of treating or inhibiting the growth of a tumor, the method comprising administering to a subject in need thereof a therapeutically effective amount of each inhibitor.
Citation Information
Patent Citations
Methods for treating skin infections by administering il-4r antagonists
JP2017512193A
US1105020212-172013
